Clinical trial register · Italy

Clinical Trials in Florence, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC

6778

Studies in scope

all four open statuses

4069

Recruiting now

open to new participants

1018

Lead sponsors

across recruiting studies

Top sites

Milan 2843 Bologna 1305 Roma 1274 Naples 984 Rome 967

Trials with a site in Florence

Status

Study

Lead sponsor

Phase

Enrol

Sites in Italy

Start

Not yet open

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,180

Bologna, Forlì, Florence, Rome, Messina, Naples, Padova, Pisa

2027-11-23

Not yet open

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

2,380

Florence, Palermo

2026-12-16

By invitation

Management of Non Emergency Adhesive Small Bowel Obstruction:

NCT07860177SBO - Small Bowel Obstruction

Azienda Sanitaria di Firenze

Observational

690

Florence

2026-11-01

Not yet open

A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

NCT07830732Haemophilia A

Novo Nordisk A/S

Phase 3

Naples, Florence, Milan, Padova

2026-10-09

Not yet open

TRIDERM D.S. Crema Normalizzante for Neonatal Hyperseborrhea (Cradle Cap) and Associated Cutaneous Manifestations of Mild-to-Moderate Seborrheic Dermatitis in Children Aged 0 to 3 Years

NCT07860788Cradle Cap, Seborrheic Dermatitis

ICIM International S.r.l.

Not applicable

Florence

2026-10

Recruiting

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases

DrugZenpep

Aimmune Nestlé Health Science US R&D, LLC

Phase 2

Catania, Rozzano, Messina, Florence, Milan, Roma

2026-10

Recruiting

Evaluation of Diagnostic Accuracy and Clinical Performance of the UIICORE BSI Test

NCT07859852Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia

Deepull Diagnostics S.L.

Observational

1,500

Florence, Perugia

2026-09-21

Recruiting

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

NCT07851025Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·Bevacizumab

AstraZeneca

Phase 3

950

Florence, Genova

2026-09-16

Not yet open

Biomarkers of Neurodegeneration, Synaptic Plasticity and Neuroinflammation in Dravet Syndrome

NCT07801404Dravet Syndrome (DS)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Observational

Ancona, Florence, Genova, Messina, Milan, Roma, Rome, Verona

2026-09-15

Recruiting

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

NCT07648264Secondary Immune Deficiency

DrugHizentra

CSL Behring

Phase 3

Rome, Brescia, Varese, Candiolo, Catania, Florence, Milan

2026-09-15

Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161Myelofibrosis, Anemia

DrugElritercept

Takeda

Phase 3

324

Bologna, Cona, Meldola, Rome, Milan, Ancona, Catania, Florence

2026-09-10

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Bari, Bergamo, Bologna, Catania, Florence, Genova, Meldola, Milan

2026-09-08

Not yet open

Cross-cultural Adaptation and Multicenter Validation of the Italian Versions of the Brief Evaluation of Receptive Aphasia (BERA) and SWallowing Assessment in Disorders of Consciousness (SWADOC)

NCT07711119Consciousness Disorders, Severe Acquired Brain Injury

Alfonso Magliacano

Observational

Sant'Angelo dei Lombardi, Florence, Milan

2026-09-01

Not yet open

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336Diabetes Mellitus, Type 2

DrugsDulaglutide·Orforglipron

Eli Lilly and Company

Phase 3

170

Ancona, Florence, Genova, Messina, Milan, Naples, Verona

2026-09

Not yet open

Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

NCT07699107Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior

DrugsHumira·Adalimumab

Nisha Acharya

Phase 4

160

Florence

2026-09

Not yet open

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

NCT07817875Obesity

DrugTirzepatide

Eli Lilly and Company

Phase 3

150

Florence, Modena, Novara, Parma, Roma

2026-09

Recruiting

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

1,072

Brescia, Cona, Florence, Milan, Roma

2026-08-31

Recruiting

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07771465Symptomatic Genetic Dilated Cardiomyopathy (DCM)

DrugDanicamtiv

Kardigan, Inc.

Phase 3

332

Bari, Florence, Milan, Padova, Pavia, Roma, Rozzano, Trieste

2026-08-26

Recruiting

A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

NCT07742735Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)

DrugApraglutide

VectivBio AG

Phase 3

124

Pavia, Padova, Bologna, Florence, Milan, Torino

2026-08

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Ancona, Bari, Florence, Milan, Modena, Naples, Roma

2026-07-27

Recruiting

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

NCT06987539Generalized Myasthenia Gravis

DrugInebilizumab

Amgen

Phase 2

Florence

2026-07-21

Recruiting

Wearable Blood-Pressure Monitoring Comparison Study

NCT07719660Hypertension, Blood Pressure Monitoring, Wearable Devices, Photoplethysmography

Technische Universität Dresden

Observational

120

Florence

2026-07-20

Recruiting

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284High-risk Muscle Invasive Urothelial Carcinoma

DrugsRilvegostomig·Enfortumab Vedotin·Dato-DXd·Opdivo

AstraZeneca

Phase 3

915

Bari, Florence, Padova, Roma, Rozzano, Tricase

2026-07-16

Recruiting

A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

NCT07585097Alagille Syndrome

Ipsen

Observational

Florence, Naples, Padova, Roma, Torino, Udine

2026-07-10

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Bari, Florence, Milan, Naples, Palermo, Roma, Verona

2026-07-10

Not yet open

AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation

NCT07604727Atrial Fibrillation (AF), Heart Failure, Cardiac Pacing

University Medical Center Groningen

Not applicable

292

Florence, Lavagna, Milan, Nola, Reggio Emilia, Roma, Tricase

2026-07

Recruiting

Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions

NCT07080970Acute Myeloid Leukemia, NPM1 Mutation

Gruppo Italiano Malattie EMatologiche dell'Adulto

Observational

220

Florence

2026-07

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

Bologna, Catania, Chieti, Florence, Latina, Milan, Pisa, Ravenna

2026-06-29

Recruiting

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests

NCT07106632Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer

UNICANCER

Phase 3

3,380

Aviano, Bergamo, Carpi, Crema, Florence, Genova, Lecco, Meldola

2026-06-26

Recruiting

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

NCT07039422Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

Florence, Roma, Trieste, Vicenza

2026-06-26

Recruiting

Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance

NCT07855679Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension, Right Ventricular Dysfunction, Pulmonary Embolism (PE)

Azienda Ospedaliero-Universitaria Careggi

Observational

5,000

Bagno a Ripoli, Borgo San Lorenzo, Empoli, Florence, Pescia, Pistoia, Prato, Lido di Camaiore

2026-06-19

Recruiting

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

NCT07154745Paroxysmal Nocturnal Hemoglobinuria

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

Rome, Florence, Torino

2026-06-11

Active, closed

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugsCliramitug·Eplontersen

AstraZeneca

Phase 2

326

Bologna, Florence, Milan, Padova, Pavia, Pisa, Torino, Torrette - Ancona

2026-06-11

Recruiting

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

NCT07453095Mantle Cell Lymphoma

DrugGlofitamab

Fondazione Italiana Linfomi - ETS

Phase 2

Alessandria, Bologna, Brescia, Florence, Genova, Milan, Palermo, Pescara

2026-06-05

Recruiting

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

NCT07519902Persistent Corneal Epithelial Defect

DrugCenegermin

Dompé Farmaceutici S.p.A

Phase 3

150

Perugia, S. Andrea Delle Fratte, Florence, Milan, Pavia, Roma

2026-06-02

Not yet open

Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

NCT07460245Urothelial Carcinoma

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2

144

Bari, Bologna, Meldola, Foggia, Florence, Genova, Province of Macerata, Milan

2026-06

Recruiting

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

NCT07470879Colitis, Ulcerative

DrugEtrasimod

Pfizer

Phase 2

Bergamo, Milan, Florence

2026-05-28

Recruiting

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)

DrugsPelabresib·Ruxolitinib

Novartis Pharmaceuticals

Phase 3

460

Meldola, Florence, Padova, Roma, Verona, Novara

2026-05-27

Recruiting

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT07422480Myelodysplastic Syndrome, Anemia

DrugsElritercept·Epoetin Alfa

Takeda

Phase 3

300

Florence, Rozzano, Pavia, Roma, Candiolo, Bologna, Milan, Naples

2026-05-21

Recruiting

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

NCT07416526Hemophilia A

Hoffmann-La Roche

Phase 3

138

Milan, Rozzano, Florence

2026-05-15

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Ancona, Bergamo, Bologna, Brescia, Cona, Florence, Pozzilli, Milan

2026-05-11

Recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031Solid Tumors

DrugsAdagrasib·Fluorouracil·Leucovorin·Cetuximab

Mirati Therapeutics Inc.

Phase 2

170

Rome, Bologna, Florence, Meldola, Milan, Orbassano, Pesaro, Roma

2026-05-06

Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Phase 3

876

Bergamo, Milan, Florence, Perugia, Novara, Roma

2026-05-04

Recruiting

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

NCT07483073Colitis, Ulcerative, Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Florence, Milan, Monza, Negrar, Roma, Rozzano

2026-05-04

Recruiting

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

NCT07483099Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Florence, Milan, Monza, Negrar, Roma, Rozzano

2026-05-04

Active, closed

Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms

NCT07825207Myelodysplastic Neoplasm, Myelodysplastic Syndrome

DrugEltrombopag

Fondazione Italiana Sindromi Mielodisplastiche-ETS

Observational

100

Alessandria, Bari, Bologna, Brescia, Candiolo, Florence, Genova, Mantua

2026-05-01

Not yet open

Standardized Italian netwoRk Enrolling iNdividuals With Islet-Autoantibodies

NCT07503366Type 1 Diabetes (T1D), Autoantibodies, Hyperglycemia, Impaired Glucose Tolerance (Prediabetes)

Società Italiana di Endocrinologia e Diabetologia Pediatrica

Observational

300

Ancona, Bari, Bolzano, Caserta, Catanzaro, Crotone, Florence, L’Aquila

2026-05

Not yet open

Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment

NCT07476105Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B

Fondazione Italiana Linfomi - ETS

Not applicable

170

Ancona, Avellino, Aviano, Bari, Brescia, Cagliari, Florence, Milan

2026-05

Recruiting

Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

NCT07447648Homozygous Familial Hypercholesterolemia (HoFH), Coronary Computed Tomography Angiography

Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)

Observational

Caserta, Catania, Cinisello Balsamo, Florence, Naples, Padova, Palermo, Roma

2026-04-30

Recruiting

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

NCT07416604Hemophilia A

DrugEmicizumab

Hoffmann-La Roche

Phase 3

360

Naples, Milan, Rozzano, Florence

2026-04-27

Recruiting

PACE Study: School-Based Mindfulness and Compassion Interventions for Children

NCT07398781School-based Intervention, Mindfulness-based Intervention, Compassion, Emotion Regulation

IRCCS Fondazione Stella Maris

Not applicable

500

Florence, Pisa, Roma

2026-04-13

Recruiting

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

NCT07430306Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

245

Brescia, Catania, Ferrara, Florence, Milan, Padova, Pisa, Roma

2026-04-13

Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495Carcinoma, Renal Cell

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 3

758

Meldola, Rozzano, Catselfranco Veneto, Florence, Bari, Bologna, Milan, Perugia

2026-04-09

Not yet open

Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?

NCT07295522Heart Failure, Acute Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF)

DrugGDMT

IRCCS Policlinico S. Donato

Phase 4

368

San Donato Milanese, Ancona, Bari, Cecina, Ferrara, Florence, Milan, Pisa

2026-04-08

Recruiting

Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE)

NCT07580196Prostate Cancer

University of Turin, Italy

Not applicable

820

Rozzano, Bologna, Florence, Foggia, Genova, Milan, Modena, Naples

2026-03-30

Recruiting

Transition to KPL-387 Monotherapy Dosing & Administration Study

NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis

DrugKPL-387

Kiniksa Pharmaceuticals International, plc

Phase 2

120

Florence, Genoa, Milan, Padua, Udine, Varese

2026-03-25

Recruiting

Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis

NCT07474831Recurrent Bacterial Vaginosis

Liaquat University of Medical & Health Sciences

Not applicable

132

Forlì, Ravenna, Rome, Brescia, Pavia, Turin, Catania, Florence

2026-03-23

Recruiting

ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

NCT07381764Metastatic Colorectal Cancer (CRC)

DrugsErbitux·Trifluridine/Tipiracil·Cetuximab·Irinotecan

Gruppo Oncologico Italia Meridionale

Phase 2

150

Alessandria, Ancona, Aviano, Caserta, Castellana Grotte, Catania, Catanzaro, Florence

2026-03-20

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)

DrugEnpatoran

EMD Serono Research & Development Institute, Inc.

Phase 3

202

Florence, Roma

2026-03-10

Recruiting

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration

Novartis Pharmaceuticals

Phase 2

272

Florence, Milan, Roma

2026-03-09

Recruiting

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

DrugsIdelalisib·Pirtobrutinib

Eli Lilly and Company

Phase 4

150

Alessandria, Florence, Messina, Monza, Perugia, Rome, Terni

2026-03-09

Recruiting

Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC

NCT07479277Non-Small Cell Lung Cancer, Postoperative Air Leak, NSCLC

Fondazione del Piemonte per l'Oncologia

Not applicable

160

Candiolo, Bolzano, Florence, Milan, Palermo, Pisa

2026-02-27

Recruiting

A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy

NCT07595653Generalized Myasthenia Gravis (gMG), gMG

argenx

Observational

100

Acquaviva delle Fonti, Ancona, Bari, Bergamo, Bologna, Catanzaro, Florence, Genova

2026-02-25

Recruiting

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

NCT07298044Transthyretin Amyloid Cardiomyopathy

DrugAcoramidis

Bayer

Phase 4

Bergamo, Bologna, Florence, Lecce, Milan, Naples, Padova, Pavia

2026-02-13

Recruiting

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07210723Symptomatic Genetic Dilated Cardiomyopathy

DrugDanicamtiv

Kardigan, Inc.

Phase 2/3

332

Bari, Florence, Milan, Padova, Pavia, Roma, Rozzano, Trieste

2026-02-13

Recruiting

Benralizumab Effectiveness in EGPA

NCT07815886Eosinophilic Granulomatosis With Polyangiitis (EGPA)

DrugBenralizumab

European EGPA Study Group

Observational

100

Florence

2026-02-11

Active, closed

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441Multiple Myeloma

DrugRamantamig

Janssen Research & Development, LLC

Phase 2

168

Bergamo, Bologna, Cuneo, Florence, Palermo, Pavia, Pescara, Roma

2026-02-08

Recruiting

Outcomes in ARMs: Comparison Between Surgical Techniques in Patients With Perineal or Vestibular Fistula - a Multicenter Italian Study

NCT07438691Anorectal Malformations

Meyer Children's Hospital IRCCS

Observational

500

Florence, Bergamo, Brescia, Catania, Lecce, Modena, Novara, Padova

2026-02-05

Recruiting

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

300

Ancona, Florence, Messina, Naples, Novara, Padova, Verona

2026-02-05

Recruiting

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN

DrugsNucresiran·Vutrisiran

Alnylam Pharmaceuticals

Phase 3

125

Florence, Milan, Padova, Pavia, Roma

2026-02-03

Not yet open

MASKd: a Study on Kawasaki Disease (KD) Complicated by Macrophage Activation Syndrome (MAS)

NCT07491926Kawasaki Disease, Macrophage Activation Syndrome (MAS)

Meyer Children's Hospital IRCCS

Observational

150

Florence

2026-02

Not yet open

XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients

NCT07381777Locally Advanced Rectal Cancer (LARC)

DrugsXelox·Dostarlimab

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2

270

Arezzo, Aviano, Bologna, Brescia, Catania, Cuneo, Florence, Genova

2026-01-31

Recruiting

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190Uveal Melanoma

DrugDarovasertib

IDEAYA Biosciences

Phase 3

520

Naples, Milan, Perugia, Florence, Pisa, Rome

2026-01-25

Recruiting

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia

DrugAtumelnant

Crinetics Pharmaceuticals Inc.

Phase 2/3

153

Naples, Genoa, Milan, Florence

2026-01-22

Recruiting

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT07277231Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Venclyxto·Acalabrutinib·Venclexta

BeOne Medicines

Phase 3

500

Bologna, Florence, Milan, Padova, Roma

2026-01-22

Recruiting

Prevalence of Mild Cognitive Impairment and Dementia in Patients Admitted to Non-neurological Rehabilitation Wards

NCT07731334MCI, Mild Cognitive Impairment (MCI), Mild Cognitive Impairment, Cognitive Deficit

Fondazione Don Carlo Gnocchi ETS

Not applicable

384

Florence, Milan

2026-01-20

Recruiting

High Fat Diet for Cardiac Metabolic Reprogramming

NCT06747429Non-ischemic Dilated Cardiomyopathy, Heart Failure With Reduced Ejection Fraction

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Not applicable

Florence

2026-01-15

Recruiting

REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT07229235Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis Pharmaceuticals

Observational

Alessandria, Avellino, Brescia, Florence, Genova, Milan, Palermo, Roma

2026-01-13

Recruiting

Clinical, Biochemical and Epigenetic Profile of Pediatric Behçet Disease

NCT07375940Behcet Disease and Vascular Involvement

Meyer Children's Hospital IRCCS

Not applicable

Florence

2026-01-12

Not yet open

Endobronchial Valve in Tubercular and NTM Pulmonary Cavities.

NCT07296055Multidrug Resistance Tubercolosis, Non Tubercolar Micobacteriosis

Azienda Ospedaliero-Universitaria Careggi

Not applicable

Florence

2026-01-12

Recruiting

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

150

Ancona, Bologna, Cagliari, Florence, Milan, Naples, Novara, Padova

2026-01-12

Recruiting

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

NCT07227454Depressive Disorder, Major

DrugsEsketamine·Midazolam

Janssen Research & Development, LLC

Phase 3

258

Acireale, Cagliari, Florence, Foggia, Genova, Merano, Naples, Sassari

2026-01-08

Recruiting

Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder

NCT07224581GRIN-related Neurodevelopmental Disorder

DrugRadiprodil

GRIN Therapeutics, Inc.

Phase 3

100

Florence, Pavia, Roma

2026-01-05

Recruiting

Nerve-SPARing Robotic Prostatectomy: The Impact of Patient Baseline Profiles on Erectile Function

NCT07747272Prostate Cancer, Prostatectomy, Robotic Surgery, Erectile Function

University of Florence

Observational

300

Florence

2026-01-01

Not yet open

Tridimensional Robotic Assessment of Neglect in Brain Injured Patients

NCT07290218Neglect, Brain Injured Patients, Stroke, Unilateral Spatial Neglect (USN)

Fondazione Don Carlo Gnocchi ETS

Observational

Sant'Angelo dei Lombardi, Florence, Pisa

2026-01-01

Recruiting

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

NCT07330245Lupus Erythematosus, Systemic

DrugAnifrolumab

AstraZeneca

Observational

218

Monserrato, Cona, San Giovanni Rotondo, Rozzano, Ancona, Bari, Brescia, Florence

2025-12-31

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

Brescia, Catania, Florence, Lecco, Milan, Naples, Parma, Pisa

2025-12-29

Recruiting

A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy

NCT07218523Bowel Cleansing Prior to Clinical Procedures

DrugsPicoprep·Plenvu

Norgine

Phase 3

212

Bergamo, Florence, Messina, Milan, Naples, Roma

2025-12-29

Recruiting

USING A DECISION-MAKING SYSTEM TO SUPPORT THE MANAGEMENT OF FEVER AND ACUTE PAIN IN CHILDREN

NCT07344090Fever, Acute Pain

Qwince Innovation S.r.l.

Not applicable

100

Florence

2025-12-28

Recruiting

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

NCT06932562Multiple Myeloma

DrugsLinvoseltamab·Daratumumab·Lenalidomide·Dexamethasone

European Myeloma Network B.V.

Phase 3

1,000

Ancona, Cuneo, Florence, Genova, Legnano, Meldola, Milan, Reggio

2025-12-23

Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NCT07174336Breast Neoplasms, Neoplasm Metastasis

DrugsTersolisib·Exemestane·Anastrozole·Abemaciclib

Eli Lilly and Company

Phase 3

800

Bergamo, Bologna, Florence, Genova, Meldola, Milan, Misterbianco, Monza

2025-12-22

Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946Prostatic Neoplasms, Castration-Resistant

DrugsPasritamig·Prednisone/Prednisolone·Docetaxel

Janssen Research & Development, LLC

Phase 3

800

Florence, Localita La Schiana Pozzuoli, Milan, Roma, Torino

2025-12-19

Recruiting

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

NCT07285460Hemophilia

DrugsAntithrombin·Clotting factor concentrates·Fitusiran

Sanofi

Phase 3

Florence, Milan, Rozzano

2025-12-18

Recruiting

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

NCT07543419Hidradenitis Suppurativa

Novartis Pharmaceuticals

Observational

250

Ancona, Bari, Brescia, Cona, Florence, Genova, Lecce, Messina

2025-12-17

Recruiting

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery

Ascendis Pharma A/S

Phase 3

186

Florence, Genova, Naples, Trieste

2025-12-12

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Tricase, Roma, Padova, Florence, Milan

2025-12-11

Recruiting

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779Ovarian Cancer

DrugINCB123667

Incyte Corporation

Phase 3

466

Alba, Alessandria, Aviano, Bologna, Florence, Lecco, Milan, Mirano

2025-12-09

Active, closed

Central Sensitization in Women With Adenomyosis: Prevalence, Risk Factors, and Therapeutic Failure

NCT07455721Adenomyosis

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

1,200

Bologna, Cagliari, Catanzaro, Florence, Milan, Palermo, Potenza, Roma

2025-12-09

Recruiting

REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)

NCT07412782Osteogenesis Imperfecta, Osteoporosis, Hypogonadisms, Neoplasia

Meyer Children's Hospital IRCCS

Not applicable

100

Florence

2025-12-04

Recruiting

Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.

NCT07363304Cystic Fibrosis (CF)

DrugsTrikafta·Elexacaftor/Tezacaftor/Ivacaftor

Meyer Children's Hospital IRCCS

Observational

150

Bari, Milan, Naples, Roma, Torino, Florence

2025-12-02

Recruiting

A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

NCT07203768Polycythemia Vera, Thrombocythemia

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

678

Pavia, Vicenza, Alessandria, Bergamo, Bologna, Brescia, Florence, Milan

2025-12-01

Recruiting

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease

DrugOrforglipron

Eli Lilly and Company

Phase 3

7,140

Bologna, Brescia, Ferrara, Florence, Genova, Milan, Monza, Palermo

2025-12-01

Recruiting

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

NCT07395232Atopic Keratoconjunctivitis

DrugDFL24498

Dompé Farmaceutici S.p.A

Phase 3

153

Bologna, Chieti, Florence, Roma, Verona

2025-12-01

Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan·Cabozantinib

Merck Sharp & Dohme LLC

Phase 3

904

Naples, Rome, Milan, Rozzano, Orbassano, Florence, Castelfranco Veneto, Peschiera del Garda

2025-11-26

Recruiting

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

NCT07211958Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 3

468

Monza, Pesaro, Alessandria, Bergamo, Bologna, Brescia, Candiolo, Florence

2025-11-25

Recruiting

A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

NCT07227857Epileptic Encephalopathy

Institut de Recherches Internationales Servier

Phase 1/2

Florence, Roma

2025-11-24

Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832Metastatic Colorectal Cancer (CRC)

DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin

Summit Therapeutics

Phase 3

600

Roma, Aviano, Brescia, Florence, Genova, Meldola, Milan, Pisa

2025-11-18

Recruiting

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

NCT06887803Myelofibrosis (MF)

DrugRoginolisib

iOnctura

Phase 1/2

Florence, Rozzano, Bologna, Meldola, Udine

2025-11-17

Active, closed

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT07036523Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim

Phase 2

Bergamo, Florence, Naples, Roma, Torino

2025-11-13

Recruiting

Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score

NCT07681583Pneumonia, Fungal Pneumonia, Aspergillosis Pneumonia, Pulmonary Aspergillosis

Azienda Ospedaliero-Universitaria Careggi

Observational

400

Florence

2025-11-13

Active, closed

Effect of Treatment With Butyric Acid in Anorexia Nervosa

NCT07289581Anorexia Nervosa, Gut Microbiota, Weight Trajectory

Azienda Ospedaliero-Universitaria Careggi

Not applicable

Florence

2025-11-12

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 3

670

Aviano (PN), Bari, Brescia, Florence, Meldola (FC), Orbassano (TO), Padova, Parma

2025-11-07

Recruiting

ASMact: Study on Management of Bronchial Asthma

NCT07412769Asthma Acute, Asthma Childhood, Asthma in Children, Asthma Crisis

Meyer Children's Hospital IRCCS

Observational

500

Ferrara, Florence

2025-11-05

Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Cona, Florence, Rome, Ancona, Reggio Emilia

2025-11-05

Recruiting

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

NCT07108283Nonsegmental Vitiligo

DrugZasocitinib

Takeda

Phase 2

200

Rozzano, Rome, Brescia, Florence

2025-11-03

Recruiting

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

NCT07203001Still´s Disease

DrugArumakimig

Novartis Pharmaceuticals

Phase 2

Florence, Genova, Roma

2025-11-03

Recruiting

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 3

100

Aviano, Florence, Meldola, Milan, Naples, Roma

2025-10-30

Recruiting

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

NCT07220564Haemophilia A

Novo Nordisk A/S

Phase 1

Florence, Naples

2025-10-23

Recruiting

GenoDrugP 2025: Study on Three-dimensional Models Derived From Brain Tumors in Pediatric Patients

NCT07417072Pediatric Brain Tumors, Genomics, Epigenetic

Meyer Children's Hospital IRCCS

Not applicable

Florence

2025-10-21

Recruiting

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

NCT07407465Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma

DrugsTrastuzumab deruxtecan·Capecitabine·Bevacizumab

Gruppo Oncologico del Nord-Ovest

Phase 2

Bari, Florence, Milan, Ravenna, Rozzano, Tricase, Modena, Roma

2025-10-20

Recruiting

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy

NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Stemline Therapeutics, Inc.

Observational

140

Alessandria, Bari, Bologna, Brescia, Catania, Florence, Milan, Naples

2025-10-17

Recruiting

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

NCT07115004Von Willebrand Disease (VWD)

DrugVGA039

Vega Therapeutics, Inc

Phase 3

Milan, Florence

2025-10-15

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

Bergamo, Bologna, Florence, Milan, Naples, Padova, Palermo, Roma

2025-10-15

Active, closed

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

NCT07157254Angelman Syndrome

DrugApazunersen

Ultragenyx Pharmaceutical Inc

Phase 2

Florence, Milan, Rome

2025-10-13

Recruiting

Reference Intervals With Indirect Methods in Italy

NCT07433777Reference Intervals

Centro di Riferimento Oncologico - Aviano

Observational

1,000,000

Altamura, Ancona, Arezzo, Belluno, Florence, Milan, Modena, Monza

2025-10-08

Recruiting

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

NCT07023614Non-obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals, Inc.

Phase 2

165

Florence, Massa, Milan, Naples

2025-10-06

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Milan, Florence, Ancona, Foggia

2025-10-03

Recruiting

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)

DrugNNC6019-0001

Novo Nordisk A/S

Phase 3

1,280

Ancona - Torrette, Bologna, Bolzano, Brescia, Cona, Florence, Ivrea, Lecco

2025-10-02

Recruiting

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

NCT07040774Genetic Disease, Immune Dysfunction, Neurological Diseases or Conditions, Autoimmune Diseases

Imagine Institute

Observational

500

Florence

2025-10-01

Recruiting

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

882

Bologna, Florence, Milan, Negrar-Verona, Roma, Rozzano, San Giovanni Rotondo

2025-10-01

Recruiting

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

NCT07008118Myeloproliferative Neoplasms

Incyte Corporation

Phase 1

120

Bergamo, Florence, Milan, Verona

2025-10-01

Not yet open

LUpus Eritematoso Sistemico NETwork and Registry

NCT07175610Systemic Lupus Erythematous (SLE)

Società Italiana di Allergologia, Asma e Immunologia Clinica

Observational

1,500

Ancona, Bari, Battipaglia, Cagliari, Florence, Mantua, Milan, Naples

2025-09-30

Recruiting

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

NCT07022483Endometrial Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

710

Bari, Bologna, Florence, Lecco, Milan, Torino

2025-09-30

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

Aviano, Rome, Roma, Florence, Verona, Bergamo, Caserta, Genova

2025-09-29

Recruiting

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT07190196Immunoglobulin G4 Related Disease

DrugRilzabrutinib

Sanofi

Phase 3

124

Florence, Milan, Verona

2025-09-26

Recruiting

International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study

NCT07164378Age - Related Macular Degeneration (AMD)

VisionCare, Inc.

Not applicable

Bari, Bergamo, Ferrara, Florence, Roma

2025-09-23

Recruiting

Functional Electrical Stimulation to Treat Critical Neuromyopathy After Severe Stroke: a Pilot Study.

NCT07130929Intensive Care Unit (ICU) Acquired Weakness (ICU - AW), Acquired Brain Injury (Including Stroke)

Fondazione Don Carlo Gnocchi ETS

Not applicable

Florence

2025-09-23

Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520Non-small Cell Lung Cancer

DrugsBNT326·Pumitamig

BioNTech SE

Phase 1/2

880

Alessandria, Catania, Florence, Milan, Roma

2025-09-22

Active, closed

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

NCT06946797Non-Small Cell Lung Cancer

DrugsNivolumab and rHuPH20·Yervoy·Ipilimumab·Pemetrexed

Bristol-Myers Squibb

Phase 2

Meldola, Udine, Bergamo, Florence, Novara

2025-09-19

Active, closed

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

413

Brescia, Florence, Milan, Padova, Pavia, Roma

2025-09-13

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Florence, Genova, Milan, Naples, Padua, Perugia, Rome, Rozzano

2025-09-08

Recruiting

Digital vs. Conventional Indirect Bonding.

NCT07692880Malocclusion

Azienda Ospedaliero-Universitaria Careggi

Not applicable

Florence

2025-09-03

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289Colorectal Cancer

DrugTelisotuzumab Adizutecan

AbbVie

Phase 2

140

Florence, Rozzano, Naples

2025-09-02

Recruiting

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Eli Lilly and Company

Phase 3

10,450

Arzignano, Baggiovara, Bologna, Caserta, Ferrara, Ferrara (Cona), Florence, Genova

2025-09-02

Not yet open

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

NCT07005882Breast Cancer Patients, Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR+/HER2- Breast Cancer, Radiation Therapy

DrugElacestrant

Azienda Ospedaliero-Universitaria Careggi

Phase 2

Florence

2025-09-01

Not yet open

Long-term Assessment of Chlormethine Gel in Mycosis Fungoides

NCT07046663Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Fondazione Italiana Linfomi - ETS

Observational

190

Ancona, Bergamo, Bologna, Brescia, Cagliari, Catania, Florence, Genova

2025-09

Not yet open

Clinical validatiOn of an AI-based DEcision Support System for Robotic Upper Limb Rehabilitation in Patients With Stroke. A CO-AIDER Study.

NCT07199322Stroke, Stroke Ischemic, Stroke Hemorrhagic, Upper Limb Rehabilitation

Fondazione Don Carlo Gnocchi ETS

Not applicable

100

Sant'Angelo dei Lombardi, Rovato, Florence, Tricarico, Pisa, Acerenza, Roma, La Spezia

2025-09

Not yet open

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

NCT07124884Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer

Federation Francophone de Cancerologie Digestive

Phase 2

300

Aviano, Catania, Florence, Livorno, Meldola, Milan, Monserrato, Padova

2025-08-31

Recruiting

TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders

NCT07377032GRIN-related Disorders, GRIN1, GRIN2A, GRIN2B

Meyer Children's Hospital IRCCS

Phase 3

Florence

2025-08-29

Recruiting

Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients

NCT06933277Multiple Myeloma

Gruppo Italiano Malattie EMatologiche dell'Adulto

Observational

159

Florence

2025-08-29

Recruiting

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer

DrugsCapivasertib·Fulvestrant

Relay Therapeutics, Inc.

Phase 3

540

Ancona, Brescia, Candiolo, Cona, Florence, Livorno, Meldola, Milan

2025-08-26

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07018700Episodic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

990

Florence, Milan, Pavia, Roma

2025-08-21

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713Chronic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

780

Florence, Milan, Pavia, Roma

2025-08-21

Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

NCT07086976Autoimmune Haemolytic Anaemia

DrugRilzabrutinib

Sanofi

Phase 3

Florence, Genoa, Milan, Naples, Meldola, Novara, Palermo, Trieste

2025-08-18

Recruiting

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT07059000Chronic Primary Immune Thrombocytopenia (ITP)

DrugKedrion IVIG

Kedrion S.p.A.

Phase 3

Florence, Novara, Trieste, Torino, Vicenza

2025-08-13

Recruiting

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

NCT06975865Sickle Cell Disease

DrugRilzabrutinib

Sanofi

Phase 3

192

Florence, Milan, Naples, Rome, Orbassano, Palermo, Verona

2025-08-12

Recruiting

Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

NCT06680050Non Small Cell Lung Cancer NSCLC

DrugsCeralasertib·Durvalumab

Mario Negri Institute for Pharmacological Research

Phase 2

Brescia, Florence, Genova, Milan, Padova, Parma

2025-08-07

Recruiting

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

NCT07007793Primary Hyperaldosteronism

DrugBaxdrostat

AstraZeneca

Phase 3

250

Bologna, Brescia, Florence, Milan, Torino

2025-08-07

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Florence, Genoa, Milan, Rome, Turin, Bologna, Messina, Novara

2025-08-06

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Alessandria, Aviano, Bari, Bologna, Catania, Florence, Haifa, Milan

2025-08-01

Recruiting

CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome

NCT07468461Camptodactyly, Arthropathy, Coxa Vara, Pericarditis

Meyer Children's Hospital IRCCS

Observational

Bari, Florence, Genova, Milan, Padova, Roma, Udine

2025-08-01

Recruiting

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

NCT06967480Generalized Myasthenia Gravis, Anti-AChR Antibody Positive

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Observational

Bergamo, Bologna, Brescia, Florence, Imperia, Lecco, Messina, Milan

2025-07-31

Recruiting

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

NCT07010159Pericarditis, Pericarditis Acute, Recurrent Pericarditis

DrugKPL-387

Kiniksa Pharmaceuticals International, plc

Phase 2/3

325

Florence, Genoa, Milan, Padua, Turin, Udine, Varese

2025-07-25

Recruiting

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712Gastroesophageal Adenocarcinoma

DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan

AstraZeneca

Phase 2

100

Florence, Milan, Modena, Pisa, Rozzano, Udine, Vicenza

2025-07-17

Recruiting

Urgent Carotid Endarterectomy (CEA) Versus Delayed CEA in Symptomatic Carotid Stenosis (SPREAD-STACI II)

NCT06767657Stroke, Ischemic, Transient Ischemic Accident, Endarterectomy, Carotid, Stroke Prevention

Italian Society of Vascular and Endovascular Surgery

Not applicable

456

Florence

2025-07-03

Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903Transthyretin Amyloidosis With Cardiomyopathy

DrugNucresiran

Alnylam Pharmaceuticals

Phase 3

1,750

Ancona, Bologna, Brescia, Florence, Forlì, Lecce, Milan, Naples

2025-07-02

Recruiting

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

NCT06486883Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma

DrugsCDK4/6i·Trastuzumab deruxtecan

MedSIR

Phase 2

200

Ancona, Aviano, Florence, Genova, Milan, Modena, Monza, Naples

2025-06-30

By invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637Hidradenitis Suppurativa

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

835

Catania, Chieti, Cona, Florence, Milan, Modena, Naples, Perugia

2025-06-27

Recruiting

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

NCT06998524Von Willebrand Disease, Type 3

DrugEmicizumab

Hoffmann-La Roche

Phase 3

Rome, Milan, Florence

2025-06-27

Active, closed

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

NCT06959225Hidradenitis Suppurativa

DrugRuxolitinib

Incyte Corporation

Phase 3

580

Catania, Cona, Florence, Milan, Naples, Roma, Rozzano, Torino

2025-06-23

Recruiting

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

NCT07516964Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy

Meyer Children's Hospital IRCCS

Not applicable

Bagno a Ripoli, Florence, Bologna, Genova, Parma, Pisa, Prato, Reggio Emilia

2025-06-10

Recruiting

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867Myelodysplastic Syndromes

DrugMomelotinib

GlaxoSmithKline

Phase 2

Udine, Catania, Florence, Milan, Orbassano to, Rozzano MI

2025-06-05

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Alessandria, Ancona, Bergamo, Bologna, Brescia, Catania, Florence, Genova

2025-06-04

Recruiting

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125Dravet Syndrome

DrugZorevunersen

Stoke Therapeutics, Inc

Phase 3

170

Florence, Genova, Roma

2025-06-04

Not yet open

Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism

NCT06826664Phosphate Deficiency, Phosphate Overload

F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore

Observational

100

Bari, Bologna, Brescia, Cagliari, Ferrara, Florence, Genova, Messina

2025-06-01

Not yet open

Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database)

NCT06790251Multiple Endocrine Neoplasia Type 1

F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore

Observational

600

Orbassano, Bari, Bologna, Cagliari, Cuneo, Ferrara, Florence, Genova

2025-06-01

Not yet open

Discontinuation of Tobacco Dependence in Smoking Patients With Squamous Cell Carcinoma of the Head-neck District: Multicenter Prospective Observational Study

NCT06995417Cancer of Head and Neck

Azienda Ospedaliero-Universitaria Careggi

Observational

200

Florence

2025-06

Recruiting

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

NCT06780098Lung Neoplasm

DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel

Merck Sharp & Dohme LLC

Phase 2

144

Florence, Milan, Roma

2025-05-28

Recruiting

Immunological Phenotype of Desmoid-fibromatosis-affected Patients.

NCT07496242Desmoid-Type Fibromatosis

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Observational

200

Candiolo, Florence, Milan, Padova, Palermo, Rome

2025-05-27

Recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

NCT05815927Oligometastatic Squamous Cell Carcinoma of the Head and Neck

DrugPembrolizumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

200

Bologna, Cuneo, Florence, Milan, Naples, Ravenna, Rome

2025-05-23

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Bergamo, Bologna, Brescia, Candiolo, Cremona, Florence, Meldola, Milan

2025-05-22

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

Meldola, Milan, Catania, Florence, Naples, Pisa, Roma, Torino

2025-05-22

Recruiting

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine

DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab

AstraZeneca

Phase 3

150

Florence, Orbassano, Roma

2025-05-15

Recruiting

EFESO: Study on Juvenile Onset Eosinophilic Fasciitis

NCT07348263Eosinophilic Fasciitis

Meyer Children's Hospital IRCCS

Observational

Florence, Genova, Udine

2025-05-15

Recruiting

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

NCT06780085Carcinoma, Non-Small-Cell Lung

DrugsR-DXd·Ifinatamab Deruxtecan

Merck Sharp & Dohme LLC

Phase 2

Milan, Florence, Roma

2025-05-13

Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

587

Bologna, Florence, Pavia, Pisa, Roma, Rome

2025-05-12

Recruiting

Spontaneous Eye Blinking in Disorders of Consciousness

NCT06323031Disorders of Consciousness

Fondazione Don Carlo Gnocchi ETS

Observational

Sant'Angelo dei Lombardi, Ferrara, Florence, Milan

2025-05-08

Recruiting

KETO-TUMOR: a Study on Brain Tumors and Central Obesity

NCT07396896Obese Patients, Hypothalamic Neoplasms

Meyer Children's Hospital IRCCS

Not applicable

Florence

2025-05-08

Recruiting

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285Myelodysplastic Syndromes

DrugElritercept

Takeda

Phase 3

225

Ancona, Turin, Florence, Milan, Pavia, Reggio Calabria, Rome, Rozzano

2025-05-06

Not yet open

Reliability of Sensor-Derived Measurements of the SENSorized Fugl-Meyer (FMA) in Subjects with Stroke Outcomes

NCT06893367Stroke, Sensorimotor Impairment Affecting the Upper Limb, 18 Years and Over

Fondazione Don Carlo Gnocchi ETS

Not applicable

Florence

2025-05

Active, closed

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

NCT06883240Von Willebrand Disease, Type 3

DrugsActivated Prothrombin Complex·Recombinant Factor VIIa

Hoffmann-La Roche

Observational

Rome, Milan, Florence

2025-04-29

Active, closed

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895Type 1 Diabetes, Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

905

Bologna, Catanzaro, Florence, Milan, Naples, Padova, Roma, Torino

2025-04-25

Recruiting

Lung Ultrasound for Guiding Antibiotic Use in Pediatric Pneumonia

NCT06921993Pneumonia Childhood, Pneumonia, Lung Ultrasound, Antibiotic Stewardship

Meyer Children's Hospital IRCCS

Not applicable

659

Florence, Bergamo, Bologna, Brescia, Genova, Milan, Naples, Novara

2025-04-24

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

Bari, Meldola, Naples, Orbassano, Rome, Florence, Genova, Padova

2025-04-24

Recruiting

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

NCT06462963Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Not applicable

302

Florence, Milan, Negrar, Roma, Torino

2025-04-15

Recruiting

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671CLL, Chronic Lymphocytic Leukemia

DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax

BeOne Medicines

Phase 3

250

Bari, Florence, Milan, Naples, Novara, Pavia, Perugia, Roma

2025-04-10

Recruiting

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217Lennox Gastaut Syndrome

DrugClemizole HCl

Epygenix

Phase 3

260

Genoa, Pozzilli, Catanzaro, Florence, Milan

2025-04-09

Recruiting

A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

NCT06835530Diffuse Large B Cell Non-Hodgkin Lymphoma

DrugsGolcadomide·Rituximab

Fondazione Italiana Linfomi - ETS

Phase 2

Alessandria, Pescara, Ancona, Avellino, Aviano, Brescia, Florence, Milan

2025-04-09

Recruiting

BRCA Mutation Carriers' Platform a Multicenter Study

NCT07253051BRCA1 Mutation, BRCA2 Mutation

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Observational

10,000

Avellino, Aviano, Bari, Bergamo, Catania, Cuneo, Enna, Florence

2025-04-05

Not yet open

Robotic rEhabilitation sCenario fOr patieNts With NeglECT

NCT06890481Stroke, Ischemic Stroke, Haemorrhagic Stroke, Neglect, Hemispatial

Fondazione Don Carlo Gnocchi ETS

Not applicable

Florence

2025-04-01

Not yet open

AggRegated System Of sensOrs and Multimedia Monitors: Technology for innovAtion and personalizaTion of rEhabilitation Care. (ROOMMATE)

NCT06728020Subacute Stroke, Stroke; Subacute

Francesca Cecchi

Not applicable

200

Florence

2025-04

Recruiting

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

NCT06897644Pancreatic Adenocarcinoma Advanced or Metastatic

DrugsLeucovorin·Irinotecan·Adrucil·Nab-paclitaxel

Gruppo Oncologico del Nord-Ovest

Phase 3

340

Aviano, Bari, Brescia, Crema, Cremona, Florence, Genoa, Meldola

2025-03-27

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Catania, Florence, Milan, Monza, Naples, Reggio Emilia, Roma, Rome

2025-03-27

Active, closed

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

NCT06788912Lung Neoplasm Malignant

DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Ribociclib·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 2

Florence, Milan, Roma

2025-03-20

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Cona, Florence, Milan, Montebelluna, Naples, Pavia, Roma, Sassari

2025-03-18

Active, closed

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858878Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

DrugMaridebart cafraglutide

Amgen

Phase 3

1,105

Bologna, Chieti, Florence, Milan, Palermo

2025-03-17

Recruiting

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06869551Juvenile Psoriatic Arthritis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

Naples, Florence

2025-03-13

Recruiting

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695Metastatic Colorectal Cancer

DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab

AstraZeneca

Phase 2

Bologna, Castelfranco Veneto, Florence, Milan, Naples, Pavia, Pisa, Roma

2025-03-12

Recruiting

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

NCT06788756Acute Myeloid Leukaemia (AML)

DrugCytarabine

Moleculin Biotech, Inc.

Phase 2/3

312

Bologna, Florence, Ravenna, Roma

2025-03-12

Active, closed

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858839Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

3,853

Bologna, Chieti, Florence, Milan, Palermo, Pisa, Roma

2025-03-12

Recruiting

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466Menstrual Migraine

DrugRimegepant

Pfizer

Phase 3

723

Avezzano, Rome, Bologna, Florence, Milan, Pavia, Roma

2025-03-11

Recruiting

Neonatal Intestinal Obstruction: Prenatal Factors and Postnatal Outcomes

NCT07434596Intestinal Obstruction

Meyer Children's Hospital IRCCS

Observational

Florence

2025-03-11

Recruiting

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

NCT06716814Haemophilia A (Moderate or Severe)

DrugEfanesoctocog alfa

Swedish Orphan Biovitrum

Phase 3

104

Catanzaro, Florence, Milan, Naples, Parma, Rome, Rozzano, Vicenza

2025-03-06

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

1,088

Torrette, Rome, Milan, Rozzano, Padova, Florence, Pisa

2025-03-03

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Cagliari, Florence, Milan, Naples, Padova, Rozzano, Torino, Tricase

2025-03-01

Recruiting

Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke

NCT06297863Acute Ischemic Stroke

University of Milano Bicocca

Phase 2

118

Avezzano, Florence, Messina, Monza, Roma, Udine

2025-03-01

Active, closed

A Phase 2 in Adult Subjects With Hereditary Angioedema

NCT06846398Hereditary Angioedema (HAE)

DrugBW-20805

Shanghai Argo Biopharmaceutical Co., Ltd.

Phase 2

Catania, Florence, Padova

2025-02-28

Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

600

Bari, Brescia, Catania, Chieti, Florence, L’Aquila, Milan, Naples

2025-02-28

Recruiting

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

DrugsMomelotinib·Reblozyl·Luspatercept

GlaxoSmithKline

Phase 2

Bologna, Catania, Florence, Meldola FC, Milan, Roma

2025-02-28

Recruiting

Tensi+ European Registry

NCT07205445Overactive Bladder

Stimuli Technology

Observational

500

Avellino, Florence, Modena, Montevarchi, Roma

2025-02-27

Recruiting

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

NCT06588868Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome

Fondazione Italiana Linfomi - ETS

Observational

400

Ancona, Bari, Bologna, Brescia, Cagliari, Catania, Florence, Genova

2025-02-27

Recruiting

National Multicentre Study on Lipid Profile in Noonan Syndrome and Related Disorders: Trends by Age, Gender and Genotype

NCT07464821RASopathies, Noonan Syndrome

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

200

Alessandria, Bari, Bologna, Florence, Genova, Messina, Milan, Modena

2025-02-26

Recruiting

stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database

NCT07397585Breast Cancer, Oligometastasis

Istituto Clinico Humanitas

Observational

300

Benevento, Bergamo, Brindisi, Brescia, Campobasso, Florence, Genova, Messina

2025-02-25

Active, closed

Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY

NCT05485831Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex

DrugCannabidiol

Jazz Pharmaceuticals

Observational

111

Bologna, Catanzaro, Chieti, Florence, Genova, Messina, Milan, Naples

2025-02-24

Recruiting

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

NCT06869473Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer

Gruppo Oncologico del Nord-Ovest

Phase 2

Cagliari, Catania, Florence, Milan, Rozzano, Naples, Roma

2025-02-20

By invitation

An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Through Raman Spectroscopy

NCT06875739Neurodegenerative Disorders, Parkinson Disease, Alzheimer Disease, Parkinsonian Disorders

Fondazione Don Carlo Gnocchi ETS

Observational

310

Cagliari, Florence, Milan

2025-02-14

Recruiting

Study on Plasmablastic Lymphoma Patients

NCT06781359Plasmablastic Lymphoma

Fondazione Italiana Linfomi - ETS

Observational

200

Aviano, Ascoli Piceno, Brescia, Cuneo, Florence, Milan, Monza, Novara

2025-02-14

Recruiting

MICI-BIO: Study on Patient With Chronic Inflammatory Bowel Disease

NCT07470502IBD (Inflammatory Bowel Disease)

Meyer Children's Hospital IRCCS

Not applicable

Florence

2025-02-13

By invitation

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

NCT06908226Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

324

Florence, Genoa, Milan, Pavia, Rome, Verona

2025-02-12

Recruiting

Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants

NCT06823466Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment

University of L'Aquila

Observational

200

Ancona, Bari, Bologna, Città di Castello, Ferrara, Florence, Frosinone, L’Aquila

2025-02-12

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

231

Cona, Florence, Genoa, Milan, Padua, Rome, Bologna

2025-02-12

Recruiting

Gonadic Function and Pubertal Development in Female Patients With Classic Galactosemia

NCT07461519Galactosemia

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

Bologna, Bari, Cagliari, Catania, Catanzaro, Florence, Genova, Messina

2025-02-12

Recruiting

Comparison Between CAD/CAM and Conventional Mandibular Fixed Retainers.

NCT06529601Orthodontic Retainers

Azienda Ospedaliero-Universitaria Careggi

Not applicable

Florence

2025-02-12

Active, closed

Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06806293Menstrual Migraine (MM)

DrugAtogepant

AbbVie

Phase 3

468

Florence, Milan, Naples, Rome, Latina, Pavia, Perugia, Udine

2025-02-10

Recruiting

MICRO-BRAIN 2024: Study on Pediatric Brain Tumors

NCT07417085Brain Tumor, Microbiota

Meyer Children's Hospital IRCCS

Not applicable

100

Florence

2025-02-06

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287Lung Cancer, Breast Cancer

DrugsPumitamig·Iza-bren·Osimertinib·Opdivo

Bristol-Myers Squibb

Phase 1/2

416

Aviano, Milan, Candiolo, Florence, Roma

2025-02-04

Recruiting

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment

DrugAcalabrutinib

AstraZeneca

Phase 4

Cagliari, Florence, Milan, Pavia, Perugia

2025-02-04

Recruiting

A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease

NCT07363044Crohn Disease (CD)

Alimentiv Inc.

Not applicable

378

Castellana Grotte, Florence, Milan, Roma, Rome, San Giovanni Rotondo

2025-02-01

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

588

Ancona, Brescia, Catania, Cona, Florence, Rozzano, Modena, Pisa

2025-01-31

Recruiting

LEISH-PED: Study on Leishmaniasis in Children

NCT07504757Leishmania Infantum Disease, Leishmaniasis, Visceral, Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous

Meyer Children's Hospital IRCCS

Observational

200

Florence

2025-01-30

Recruiting

Multimodal Prehabilitation in Cancer Surgery

NCT06788834Cancer Surgery

Università Vita-Salute San Raffaele

Not applicable

400

Catanzaro, Florence, Genova, Milan, Monza, Naples, Padova, Udine

2025-01-30

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Bologna, Cagliari, Florence, Milan, Naples, Padova, Palermo, Pavia

2025-01-28

Recruiting

Landiolol in Mitral Valve Surgery

NCT06793670Cardiac Failure, Low Cardiac Output Syndrome

DrugLandiolol

Università Vita-Salute San Raffaele

Phase 4

1,500

Alessandria, Torino, Catania, Florence, Foggia, Genova, Milan, Palermo

2025-01-28

Recruiting

Saliva and Extracellular Vesicles for Neurodegenerative Diseases

NCT06869135Neurodegenerative Diseases, Parkinson Disease, Alzheimer Disease, Parkinsonism

Fondazione Don Carlo Gnocchi ETS

Observational

242

Florence, Milan, Parma

2025-01-24

Recruiting

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

NCT06663098Extensive Stage Small Cell Lung Cancer (ES-SCLC)

DrugsEtoposide·Atezolizumab·Carboplatin

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2

142

Aviano (PN), Bari, Bologna, Carpi, Cremona, Cuneo, Florence, Lido di Camaiore

2025-01-24

Recruiting

GLUEPED2024: Study on the Use of Peripheral Venous Catheters in Pediatric Patients With Emergency Room Access.

NCT07450729Venous Catheterization

Meyer Children's Hospital IRCCS

Not applicable

300

Florence

2025-01-14

Active, closed

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637Breast Cancer

DrugsAtirmociclib·Abemaciclib·Ribociclib·Palbociclib

Pfizer

Phase 3

1,035

Bologna, Meldola(FC), Rome, Florence, Milan, Novara, Padova, Roma

2025-01-06

Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugPirtobrutinib

Loxo Oncology, Inc.

Phase 2

249

Bari, Cona, Florence, Milan, Novara, Padova, Palermo, Perugia

2025-01-03

Recruiting

ECD-Score: a Study on Erdheim-Chester Disease

NCT07454343Erdheim-Chester Disease (ECD)

Meyer Children's Hospital IRCCS

Observational

1,000

Florence, Milan

2024-12-23

Recruiting

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

DrugsBrivekimig·Frexalimab·Rilzabrutinib

Sanofi

Phase 2

Florence, Naples, Brescia, Monza

2024-12-19

Active, closed

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190Multifocal Motor Neuropathy (MMN), MMN

DrugsEmpasiprubart·Immunoglobulin·IVIG

argenx

Phase 3

154

Florence, Genova, Gussago, Messina, Milan, Roma, Rozzano

2024-12-18

Active, closed

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma

DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine

Arcus Biosciences, Inc.

Phase 3

610

Bologna, Cremona, Florence, Milan, Modena, Padova, Piacenza, Roma

2024-12-13

Recruiting

Evaluation of the Efficacy and Tolerability of an Exclusion Diet in Patients With Juvenile Idiopathic Arthritis

NCT06874608Juvenile Idiopathic Arthritis (JIA)

Meyer Children's Hospital IRCCS

Not applicable

Florence

2024-12-12

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Candiolo, Catania, Florence, Milan, Padova, Pisa, Rozzano, Udine

2024-12-12

Active, closed

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)

NCT07389109Acne Vulgaris

PPM Services S.A.

Phase 3

400

Ancona, Florence, Genova, Parma, Pavia, Roma, Bologna, Catania

2024-12-05

Recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation

DrugsElacestrant·Everolimus

MedSIR

Phase 3

300

Bergamo, Cagliari, Florence, Genova, Livorno, Milan, Modena, Monza

2024-12-05

Recruiting

Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.

NCT06856967Respiratory Synctial Virus Infections

DrugNirsevimab

Meyer Children's Hospital IRCCS

Observational

138

Arezzo, Bagno a Ripoli, Florence, Pisa, Pistoia, Prato, Siena

2024-12-04

By invitation

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

700

Bologna, Florence, Pavia

2024-12-03

Active, closed

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT06706817Chronic Rhinosinusitis With Nasal Polyps

AstraZeneca

Phase 3

181

Bologna, Catania, Florence, Padua, Pisa, Roma, Rozzano

2024-12-03

Recruiting

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

NCT06465953Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)

DrugsIvosidenib·Azacitidine

Institut de Recherches Internationales Servier

Phase 3

Ancona, Bologna, Florence, Milan, Pavia, Roma, Torino

2024-12-03

By invitation

PIECES - Towards Large-Scale Adaptation and Tailored Implementation of Primary Cancer Prevention Programs

NCT06718322Focus of Study: Tailored Implementation

Hidde van der Ploeg

Not applicable

100

Florence

2024-12-01

By invitation

Efficacy and Safety of XEN63 Gel Implant

NCT06844240Glaucoma

Mario Stirpe

Observational

Acquaviva delle Fonti, Altamura, Cuneo, Florence, Piacenza, Sassari, Venezia, Vercelli

2024-11-28

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Florence, Legnano, Livorno, Monza, Peschiera del Garda, Rome

2024-11-27

By invitation

Somatic and Ear Acupuncture for Dysphagia Rehabilitation and Decannulation After Severe Acquired Brain Injuries

NCT06888219Brain Injury, Cognitive Impairment, Deglutition Disorder

Fondazione Don Carlo Gnocchi ETS

Not applicable

Florence

2024-11-25

Recruiting

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT05552157Alzheimers Disease, Dementia, Alzheimers Disease, Familial

DrugRemternetug

Washington University School of Medicine

Phase 2/3

280

Brescia, Florence

2024-11-22

Recruiting

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT06647498Alzheimers Disease, Dementia, Alzheimers Disease, Familial

DrugRemternetug

Washington University School of Medicine

Phase 2/3

280

Brescia, Florence

2024-11-22

Active, closed

A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

NCT06668805Noonan Syndrome

DrugVosoritide

BioMarin Pharmaceutical

Phase 2

Florence, Genova, Roma

2024-11-22

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Florence, Legnano, Livorno, Monza, Orbassano, Padova, Peschiera del Garda, Roma

2024-11-18

Recruiting

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

NCT06672939Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

150

Florence, Novara, Verona

2024-11-18

Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

125

Florence, Modena, Novara, Parma, Roma, Verona

2024-11-18

Recruiting

Natural History of Familial Cerebral Cavernous Malformations: the CCM_Italia Cohort Study

NCT06983132CCM, Familial Cerebral Cavernous Malformation

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Observational

100

Bari, Florence, Genova, Milan, Salerno

2024-11-18

Recruiting

The Interplay Between Inborn Error of Immunity and Blood Disorders: Unravelling Immune Defects Behind Common Haematological Diseases

NCT06857604Hematologic Diseases

Meyer Children's Hospital IRCCS

Not applicable

700

Florence, Rome

2024-11-15

Active, closed

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease

DrugTaladegib

Endeavor Biomedicines, Inc.

Phase 2

213

Bologna, Padova, Florence, Catania, Milan, Turin

2024-11-15

Recruiting

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

NCT06733038Colorectal Cancer

DrugsFluorouracil·Leucovorin·Irinotecan·Adrucil

Gruppo Oncologico del Nord-Ovest

Phase 3

238

Brescia, Catania, Meldola, San Giovanni Rotondo, Florence, Tricase, Livorno, Lucca

2024-11-15

Active, closed

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT06637501Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

Brescia, Florence, Modena, Palermo

2024-11-14

Active, closed

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

367

Florence, Genoa, Milan, Pavia, Rome, Verona

2024-11-11

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT06655155Systemic Sclerosis (SSc)

argenx

Phase 2

Florence, Milan, Modena, Naples, Roma, Rozzano

2024-11-11

Active, closed

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

283

Bergamo, Florence, Milan, Naples, Padova, Pisa, Roma

2024-11-11

Recruiting

Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma

NCT06645951Parathyroid Gland Carcinoma, Parathyroid Gland Atypical Adenoma

F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore

Observational

300

Bari, Bologna, Cagliari, Ferrara, Florence, Foggia, Genova, Messina

2024-11-04

Recruiting

Auto-antibody Dosage From Blood Spots for Diagnosis of Type 1 Diabetes and Celiace Disease

NCT06849622Celiac Disease in Children, Diabetes Mellitus, Type I, Screening

Meyer Children's Hospital IRCCS

Not applicable

1,500

Florence

2024-11-04

Recruiting

Institution of an Italian Multicenter Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism

NCT06645899Hypoparathyroidism, Pseudo Hypoparathyroidism

F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore

Observational

600

Alessandria, Bari, Bologna, Brescia, Cagliari, Ferrara, Florence, Foggia

2024-11-04

Recruiting

HRQoL and Financial Toxicity in Patients With VEXAS Syndrome

NCT06657846VEXAS

Gruppo Italiano Malattie EMatologiche dell'Adulto

Observational

100

Ancona, Bergamo, Bologna, Brescia, Candiolo, Florence, Milan, Naples

2024-11-01

Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

975

Rome, Milan, Florence, Ancona

2024-10-30

Recruiting

TED_ORG: Study on Short Bowel Syndrome

NCT07400783Short Bowel Syndrome (SBS)

DrugTeduglutide

Meyer Children's Hospital IRCCS

Not applicable

Florence

2024-10-30

Active, closed

PTLD: Multicentric Retrospective Study

NCT06422715PTLD

Fondazione Italiana Linfomi - ETS

Observational

241

Milan, Aviano, Bergamo, Bologna, Brescia, Cagliari, Cuneo, Florence

2024-10-30

Recruiting

Functional MRI During Resting State in Patients with Eating Disorders

NCT06874348Anorexia Nervosa, Bulimia Nervosa

Meyer Children's Hospital IRCCS

Observational

Florence

2024-10-24

Active, closed

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

NCT06492837Follicular Lymphoma

DrugsMosunetuzumab·Zanubrutinib

Fondazione Italiana Linfomi - ETS

Phase 2

Candiolo, Alessandria, Ancona, Bologna, Brescia, Catania, Florence, Milan

2024-10-23

Active, closed

The Effectiveness of Virtual Reality in the Management of Procedural Anxiety and Pain in Children Suffering From Chronic Pathologies or Burn Injuries.

NCT06862830Anxiety, Chronic Disease, Pain

Meyer Children's Hospital IRCCS

Not applicable

260

Florence

2024-10-22

Recruiting

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

NCT06382155Idiopathic Short Stature

DrugsHuman Growth Hormone·Vosoritide

BioMarin Pharmaceutical

Phase 2

100

Florence, Roma, Genova

2024-10-21

Recruiting

Modified Widman Flap vs Fibre Retention Osseous Resective Surgery

NCT06123000Periodontitis, Periodontal Pocket, Periodontal Attachment Loss

University of Florence

Not applicable

Florence

2024-10-21

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499Primary Immune Thrombocytopenia (ITP)

DrugEfgartigimod

argenx

Phase 3

Bassano del Grappa, Florence, Milan, Novara, Ravenna, Reggio Emilia, Torino, Trieste

2024-10-18

Active, closed

Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program

NCT06253637T-Lymphocytic Leukemia, Acute

DrugDaratumumab

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

Florence, Lecce, Roma

2024-10-17

Active, closed

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

NCT06447168Primary Biliary Cholangitis

Ipsen

Observational

424

Bergamo, Catania, Florence, Milan, Novara, Roma

2024-10-14

Recruiting

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

NCT06533813Myelofibrosis

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

617

Alessandria, Bergamo, Bologna, Catania, Florence, Milan, Monza, Naples

2024-10-14

Active, closed

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic

DrugsEltrekibart·Mirikizumab

Eli Lilly and Company

Phase 2

143

Bologna, Brescia, Fano, Florence, Gazzi - Messina, Milan, Modena, Monserrato

2024-10-10

Recruiting

Evaluation of a Haptic Glove for Assessing Tactile Perception in Post-Stroke Patients

NCT06643273Stroke

Fondazione Don Carlo Gnocchi ETS

Not applicable

126

Florence, Messina, Roma

2024-10-04

Not yet open

Restoring Hand Function in Patients with Tetraplegia by Intraneural Stimulation of Peripheral Nerves

NCT06620536Tetraplegics

Azienda Ospedaliero-Universitaria Careggi

Not applicable

Florence

2024-10

Active, closed

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779Severe Asthma

AstraZeneca

Phase 3

310

Florence, Orbassano, Roma, Verona

2024-09-30

Recruiting

Diagnosis and Treatment of Late Neurological Ischemic Deficit in Patients Suffering From Subarachnoid Hemorrhage.

NCT06804421Aneurysmal Subarachnoid Haemorrhage, Delayed Ischemic Neurological Deficit

Fondazione IRCCS San Gerardo dei Tintori

Observational

1,400

Bergamo, Bologna, Brescia, San Fermo della Battaglia, Cremona, Florence, Genova, Lecco

2024-09-28

Recruiting

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

NCT06462235Gram-negative Bacterial Infection

Pfizer

Phase 2

Florence

2024-09-25

Active, closed

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394Dravet Syndrome

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

Florence, Genoa, Pavia, Rome, Verona

2024-09-25

Recruiting

Regorafenib for Recurrent Meningioma (MIRAGE Trial)

NCT06275919Meningioma, Malignant

DrugRegorafenib

Istituto Oncologico Veneto IRCCS

Phase 2

104

Meldola, Messina, Bagno a Ripoli, Aviano, Rozzano, Bari, Bologna, Florence

2024-09-23

Active, closed

Clinical Usefulness of a Multi-analyte Immunoassay for Distinguishing Bacterial and Viral Infections in Children

NCT06852846Febrile Illness

Meyer Children's Hospital IRCCS

Not applicable

100

Florence

2024-09-23

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

Bari, Parma, Rome, Genoa, Sassari, Florence, Pisa, Padova

2024-09-23

Recruiting

European Registry of Next Generation Imaging in Advanced Prostate Cancer

NCT06866782Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)

Fundacio Puigvert

Observational

600

Bologna, Florence, Milan

2024-09-17

Active, closed

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

NCT06571383Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 4

500

Florence, Milan, Roma, Trieste, Verona

2024-09-17

Recruiting

Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

NCT06836219Ovarian Cancer

Consorzio Oncotech

Observational

300

Bari, Bologna, Cuneo, Catania, Meldola, Florence, Genova, Monza

2024-09-13

Active, closed

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

DrugsABP 234·Pembrolizumab

Amgen

Phase 3

163

Cona, Cuneo, Florence, Lucca, Monserrato, Naples, Peschiera del Garda, Ravenna

2024-09-12

Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789Hemophilia B

Regeneron Pharmaceuticals

Phase 1/2

130

Florence, Milan, Rozzano, Vicenza

2024-09-11

Recruiting

National Database of the Virtual Institute of Cerebrovascular Diseases

NCT06859502Cerebrovascular Disease

Fondazione Don Carlo Gnocchi ETS

Observational

312,800

Florence

2024-09-10

Active, closed

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

NCT06243458Low Risk Myelodysplastic Syndromes

DrugRVU120

GCP-Service International West GmbH

Phase 2

Ancona, Bari, Candiolo, Florence, Milan, Reggio Calabria

2024-09-10

Recruiting

Blood Extracellular Vesicles as Predictive Recovery Biomarker After Stroke and Brain Injury

NCT06871800Stroke, Vascular Severe Brain Injury, Rehabilitation

Fondazione Don Carlo Gnocchi ETS

Observational

Florence, Milan, Torino

2024-09-09

Active, closed

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

2,099

Rozzano, Catania, Florence

2024-09-04

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

555

Avellino, Aviano, Bologna, Florence, Lecce, Meldola, Milan, Orbassano

2024-08-28

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Aviano, Florence, Lecco, Meldola, Milan, Padova, Pisa, Roma

2024-08-28

Active, closed

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311Relapsing Multiple Sclerosis

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

Cefalù, Florence, Pozzilli, Roma

2024-08-26

Recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

NCT06401356Hematologic Malignancy, Solid Tumor, Advanced Malignancies

DrugPelabresib

Novartis Pharmaceuticals

Phase 3

Florence, Varese, Novara

2024-08-13

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Florence, Milan, Naples, Padova, Roma, Rozzano, Tricase

2024-08-12

Active, closed

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT06313593Myeloproliferative Neoplasms

Incyte Corporation

Phase 1

Bologna, Florence, Milan

2024-08-08

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRestoret·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Bologna, Florence, Milan, Roma, Rome, Udine

2024-08-07

Active, closed

Evaluation of the Performance and Safety of Hyalo Gyn® Gel Compared to Placebo in Postmenopausal Breast Cancer Survivors

NCT06922136Vulvo Vaginal Atrophy

Fidia Farmaceutici s.p.a.

Not applicable

156

Bologna, Florence, Padova, Pavia, Roma, Torino, Milan

2024-08-01

Active, closed

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758Generalized Myasthenia Gravis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

146

Bologna, Florence, Genova, Milan, Palermo, Roma, Orbassano

2024-07-31

Recruiting

Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

NCT06476184Ovarian Cancer

DrugsPaclitaxel·Carboplatin

ARCAGY/ GINECO GROUP

Phase 3

250

Alessandria, Bologna, Florence, Lecco, Milan, Venice

2024-07-30

Active, closed

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816Geographic Atrophy

DrugVonaprument

Annexon, Inc.

Phase 3

659

Florence, Milan, Roma, Rome

2024-07-30

Recruiting

Real World Pediatric Oncology Rehabilitation in Italy ( ReWori )

NCT07368582Pediatric Cancer, Pediatric Cancer Patients, Pediatric Oncology, Rehabilitation

Associazione Italiana Ematologia Oncologia Pediatrica

Observational

249

Bergamo, Bologna, Bolzano, Bosisio Parini, Brindisi, Catania, Conegliano, Florence

2024-07-19

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsSotorasib·Bevacizumab-awwb·Panitumumab·Mvasi

Amgen

Phase 3

450

Brescia, Castellana Grotte, Florence, Foggia, Genova, Meldola FC, Milan, Naples

2024-07-17

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Florence, Alessandria, Bologna, Milan, Pavia, Roma, Varese

2024-07-16

Active, closed

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441Resectable Non-small Cell Lung Cancer

DrugsFianlimab·Cemiplimab·Paraplatin·Taxol

Regeneron Pharmaceuticals

Phase 2

195

Naples, Ferrara, Piacenza, Florence, Livorno, Bergamo, Milan, Pesaro

2024-07-16

Active, closed

Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

NCT06392009Tuberous Sclerosis Complex, Focal Cortical Dysplasia

DrugRadiprodil

GRIN Therapeutics, Inc.

Phase 1/2

Genoa, Florence, Roma

2024-07-10

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744Juvenile Psoriatic Arthritis

DrugsSkyrizi·Risankizumab·Adalimumab

AbbVie

Phase 3

Florence, Milan, Rome

2024-07-08

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Brescia, Cona, Florence, Milan, Naples, Reggio Emilia, Roma, Rome

2024-06-29

Recruiting

Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis

NCT06873308Schistosomiasis

IRCCS Sacro Cuore Don Calabria di Negrar

Not applicable

278

Bologna, Negrar, Florence

2024-06-28

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Cona, Florence, Rozzano, Naples, Rome, Catania, Milan

2024-06-27

Recruiting

A Registry-study of ELZONRIS in Participants With BPDCN

NCT07785154Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

DrugTagraxofusp

Stemline Therapeutics, Inc.

Observational

Alessandria, Bologna, Catania, Cuneo, Ferrara, Florence, Genova, Milan

2024-06-26

Recruiting

A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

NCT06467383Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I

MSD Italia S.r.l.

Observational

600

San Giovanni Rotondo, Brescia, Campobasso, Catania, Florence, Genova, Messina, Milan

2024-06-25

Recruiting

How Complexity and Multiple Illnesses Affect Hospitalized Patients' Health: a Multicenter Study

NCT06872632Complexity and Multiple Illnesses of Adult Hospitalized Internal Medicine Patient

Società Italiana di Medicina Interna

Observational

2,326

Bari, Bologna, Brescia, Ferrara, Florence, Messina, Milan, Modena

2024-06-24

Active, closed

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor

DrugsTemodar·Niraparib·Temozolomide

Ivy Brain Tumor Center

Phase 3

450

Bologna, Florence, Milan, Rozzano, Naples, Padova, Rome, Torino

2024-06-19

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754Non-small Cell Lung Cancer (NSCLC)

DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

550

Bari, Milan, Florence, Roma

2024-06-11

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Alessandria, Ancona, Bologna, Brescia, Catania, Florence, Forlì, Milan

2024-06-03

Active, closed

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma

DrugsVenclyxto·Ibrutinib·Venclexta·Venetoclax

Janssen Research & Development, LLC

Phase 2

333

Bari, Ferrara, Florence, Milan, Novara, Padova, Palermo, Perugia

2024-05-30

Active, closed

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

NCT06412666Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 2/3

Florence

2024-05-29

Recruiting

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06366464Prader-Willi Syndrome

DrugPitolisant

Harmony Biosciences Management, Inc.

Phase 3

134

Florence, Genova, Milan, Padova, Roma, Trieste

2024-05-28

Recruiting

MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

NCT05974462Acute Myocarditis

DrugsSolu-Medrol·Methylprednisolone

University Hospital, Antwerp

Phase 3

174

Milan, Arezzo, Bergamo, Brescia, Florence, Lecco, Pavia, Pisa

2024-05-24

Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

NCT06351631Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis

DrugBomedemstat

Merck Sharp & Dohme LLC

Phase 3

400

Florence, Alessandria, Bologna, Varese

2024-05-23

Active, closed

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302Diabetic Retinopathy

Boehringer Ingelheim

Phase 2

190

Florence, Milan, Naples, Roma, Rozzano, Torrette Di Ancona

2024-05-15

Active, closed

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

NCT06183489Smoldering Multiple Myeloma

DrugElranatamab

European Myeloma Network B.V.

Phase 2

Bari, Bergamo, Florence, Genova, Meldola, Novara, Padova, Pavia

2024-05-14

Recruiting

A Novel Accessible and Widespread Healthcare Service Model Based on Technology Innovation for Objective (Early) Diagnosis and Therapeutic Monitoring of Parkinson's Disease Promoting Continuity of Care

NCT06907589Parkinson Disease, Healthy Adult

Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna

Not applicable

250

Bagno a Ripoli, Florence, Massa, Milan

2024-05-13

Active, closed

Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients

NCT06414044Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine

DrugAtogepant

University of Florence

Observational

500

Florence, Roma

2024-05-09

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Brescia, Catania, Florence, Foggia, Forlì, Milan, Modena, Monza

2024-05-06

Recruiting

Italian Registry of Allergen ImmunoTherapy

NCT06499480Allergic Respiratory Disease

Società Italiana di Allergologia, Asma e Immunologia Clinica

Observational

5,000

Rozzano, Florence

2024-05-01

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

510

Florence, Milan, Naples, Padova, Pisa, Rome, Vimercate

2024-04-29

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Bologna, Brescia, Cagliari, Caserta, Catania, Ferrara, Florence, Foggia

2024-04-27

Recruiting

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

NCT06156774Non-hodgkin Lymphoma,B Cell

Fondazione Italiana Linfomi - ETS

Observational

130

Alessandria, Ancona, Avellino, Aviano, Brescia, Castelfranco Veneto, Florence, Milan

2024-04-18

Recruiting

MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)

NCT06602648Melanoma of Skin

University of Florence

Observational

100

Florence

2024-04-17

Active, closed

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06253221Cardiomyopathy, Hypertrophic

DrugMavacamten

Bristol-Myers Squibb

Phase 3

Florence, Genova, Naples

2024-04-17

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

Pozzilli, Milan, Rome, Florence, Bergamo, Cagliari, Catania, Chieti

2024-04-16

Recruiting

Integrated Approach in Frail Older People with Atrial Fibrillation

NCT06775028Atrial Fibrillation (AF), Hypertension, Coronary Arterial Disease (CAD), Heart Failure

Heart Care Foundation

Not applicable

1,250

Caserta, Florence, Genova, Grosseto, Monza, Milan, Piacenza, Gubbio

2024-04-11

Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

NCT05700149Nodal Marginal Zone Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Observational

300

Alessandria, Bari, Bergamo, Brescia, Catania, Cona, Florence, Messina

2024-04-11

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

Rome, Milan, Florence, Parma

2024-04-10

Active, closed

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408Sjögren's Syndrome (SS)

DrugDazodalibep

Amgen

Phase 3

434

Reggio Emilia, Udine, Rome, Milan, Novara, Florence, Verona, Catania

2024-04-08

Active, closed

HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array

NCT05952648HAP - Hospital Acquired Pneumonia, VAP - Ventilator Associated Pneumonia

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Not applicable

126

Bologna, Florence, Modena, Roma

2024-04-03

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Misterbianco, Meldola, Milan, Monza, Rome, Florence, Bergamo, Genova

2024-04-03

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727Solid Tumor, Adult

DrugsCRB-701·Anti-PD-1

Corbus Pharmaceuticals Inc.

Phase 1/2

348

Florence, Milan, Rome, Verona

2024-04-01

Recruiting

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

NCT06044623Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life, Toxicity

Region Örebro County

Phase 3

495

Florence, Prato

2024-04-01

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

Agrigento, Bologna, Brescia, Cagliari, Florence, Milan, Padova, Parma

2024-03-29

Recruiting

Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars

NCT06375941Angiosarcoma

Italian Sarcoma Group

Observational

250

Rozzano, Aviano, Orbassano, Bari, Bologna, Florence, Genova, Milan

2024-03-29

Recruiting

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

NCT06409832Migraine, Migraine With Aura, Migraine Without Aura

DrugRimegepant

University of Florence

Observational

100

Florence, Pavia

2024-03-26

Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer

Iambic Therapeutics, Inc

Phase 1

383

Florence, Milan, Naples

2024-03-25

Recruiting

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

NCT06378892Non Small Cell Lung Cancer Metastatic, ALK Gene Mutation

DrugLorlatinib

Centro di Riferimento Oncologico - Aviano

Phase 2

Aviano, Florence, Lido di Camaiore, Meldola, Monza, Padova, Parma, Perugia

2024-03-15

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

100

Florence, Genova, Milan, Padova, Roma

2024-03-14

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073Crohn's Disease

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

120

Alessandria, Bergamo, Bologna, Florence, Milan, Roma

2024-03-13

Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT05509777Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

Alessandria, Bergamo, Bologna, Florence, Milan, Roma

2024-03-13

Active, closed

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

17,300

Arzignano, Baggiovara, Bologna, Cinisello Balsamo, Ferrara, Florence, Genova, Milan

2024-03-05

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Florence, Milan, Naples, Padova, Pisa, Vicenza

2024-03-04

Recruiting

An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program

NCT06782789Diffuse Large B Cell Lymphoma (DLBCL)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

Bologna, Caserta, Catania, Ferrara, Florence, Milan, Novara, Palermo

2024-03-01

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Aviano, Bologna, Catania, Florence, Milan, Monza, Naples, Roma

2024-02-27

Recruiting

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

NCT06239311Moderate to Severe Atopic Dermatitis

DrugMethotrexate

medac GmbH

Phase 3

277

Arezzo, Ferrara, Florence, Naples, Parma, Pisa

2024-02-27

Recruiting

Validation Study of the Italian Version of the "Assessment of Life Habits 4.0" Scale (LIFE-H) for Measuring Participation in Children With Disabilities Aged 5 to 13 Years

NCT06854874Validation Study

Meyer Children's Hospital IRCCS

Observational

180

Florence

2024-02-23

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

NCT06283966COPD (Chronic Obstructive Pulmonary Disease)

AstraZeneca

Phase 3

5,250

Ancona, Florence, Genoa, Mestre, Milan, Naples, Pavia, Perugia

2024-02-21

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575Multiple Myeloma

DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide

Pfizer

Phase 3

492

Milan, Legnano, Turin, Palermo, Ancona, Florence, Pisa, Bologna

2024-02-08

Recruiting

Study on Eating Habits and Association with "omic" Profiles in Families with a Subject Affected by a Chronic Immune-mediated Inflammatory Pathology. Observational Multicenter Study.

NCT06862843Juvenile Idiopathic Arthritis (JIA), Crohn Disease (CD), Ulcerative Colitis (UC)

Meyer Children's Hospital IRCCS

Observational

Florence, Roma, Foggia, Palermo

2024-02-07

Active, closed

Active aGeing And Personalised Service's Ecosystem (AGAPE) Aims to Implement an Advanced Technology Platform That Provides Services to the Elderly, Formal and Informal Caregivers, and Caregiving Organizations

NCT06859489Older People, Digital Health Literacy

Fondazione Don Carlo Gnocchi ETS

Not applicable

Florence

2024-02-06

Recruiting

FBS-ASaP: Fibrobronchoscopy in ASpiration Pneumonia in the Emergency Department

NCT06511583Aspiration Pneumonia, Bronchoscopy

Azienda Ospedaliero-Universitaria Careggi

Observational

100

Florence

2024-02-05

Active, closed

A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease

NCT06150820Pompe Disease (Late-onset)

Astellas Gene Therapies

Not applicable

119

Florence, Gussago, Messina, Milan, Pavia, Pisa, Roma, Udine

2024-02-01

Recruiting

Mixed-method Research Protocol: Evaluation of a Relaxation Technique for Anxiety Management in Pre-surgical Pediatric Patients

NCT06846944Surgeries Requiring a Minimum One Day Hospitalization, Anxiety

Meyer Children's Hospital IRCCS

Not applicable

100

Florence

2024-01-31

Recruiting

A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

NCT06466785Anemia of Chronic Kidney Disease

DrugDarbepoetin Alfa

Genexine, Inc.

Phase 3

429

Brescia, Florence, Foggia, Genova, Pavia, Pisa, Verona

2024-01-25

Active, closed

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT06260163Colitis, Ulcerative

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

112

Bergamo, Bologna, Florence, Pescara, Roma, San Giovanni Rotondo, Trieste

2024-01-19

Recruiting

European Registry for Transperineal Laser Ablation of Prostate (TPLA) for Lower Urinary Tract Symptoms

NCT06564415Benign Prostatic Hyperplasia, Prostatic Diseases

University of Florence

Observational

2,500

Florence

2024-01-11

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,181

Bologna, Ferrara, Florence, Forlì, Messina, Milan, Naples, Padova

2024-01-11

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsErbitux·Cetuximab

AVEO Pharmaceuticals, Inc.

Phase 3

410

Bologna, Florence, Milan, Novara, Padua, Pavia, Roma

2024-01-11

Active, closed

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

NCT06079281Hypophosphatasia

DrugALXN1850

Alexion Pharmaceuticals, Inc.

Phase 3

124

Florence, Milan, Padova, Pisa, San Giovanni Rotondo, Verona

2024-01-03

Recruiting

Psychotropic-Drug-induced QT Prolongation and ECG Monitoring in the Pediatric Population

NCT06870006Eating Disorders, Mood Disorders in Children and Adolescents, Psychotic Disorder, QTc Intervals Changes

Meyer Children's Hospital IRCCS

Observational

100

Troina, Florence, Calambrone, Bologna, Cagliari, Messina

2024-01-01

Recruiting

Modelling of Correlation Between Emergency Department Admissions and Location-specific Air Quality and Weather in the Florence Urban Area

NCT06491290Emergency Service, Hospital, Air Pollution, Weather

Azienda Ospedaliero-Universitaria Careggi

Observational

480,000

Florence

2024-01-01

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Cona, Meldola, Milan, Florence, Pisa, Castelfranco Veneto, Alessandria, Ancona

2023-12-31

Recruiting

Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants

NCT06279741Bronchopulmonary Dysplasia

EXO Biologics S.A.

Phase 1/2

265

Florence, Genova, Milan, Modena, Padua

2023-12-28

Active, closed

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486Multiple Sclerosis

DrugFrexalimab

Sanofi

Phase 3

943

Augusta, Cona, Florence, Genoa, Milan, Naples, Cefalù, Rome

2023-12-27

Recruiting

Danon Disease Natural History Study

NCT06214507Danon Disease

Rocket Pharmaceuticals Inc.

Observational

Florence

2023-12-20

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318Relapsed/Refractory Multiple Myeloma (RRMM)

Janssen-Cilag Ltd.

Observational

900

Bologna, Bolzano, Brindisi, Florence, Lecce, Milan, Naples, Palermo

2023-12-18

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Bari, Meldola, Udine, Milan, Bergamo, Catanzaro, Florence, Roma

2023-12-15

Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

220

Aviano, Bergamo, Cattolica, Florence, Genova, Guastalla, Lecco, Legnano

2023-12-15

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Aviano, Florence, Milan, Modena, Naples, Padova, Pavia, Rozzano

2023-12-14

Active, closed

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473Multiple Sclerosis

DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab

Sanofi

Phase 3

1,655

Cona, Florence, Genoa, Milan, Monza, Naples, Rome, Orbassano

2023-12-13

Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugNexiguran ziclumeran

Intellia Therapeutics

Phase 3

1,200

Bologna, Cona, Florence, Genova, Pavia, Pisa, Trieste

2023-12-13

Active, closed

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586Type 1 Diabetes Mellitus

DrugFrexalimab

Sanofi

Phase 2

197

Torette, Florence, Milan, Naples, Rome, Novara, Varese, Verona

2023-12-11

Active, closed

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06132256Idiopathic Pulmonary Fibrosis

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

145

Foggia, Milan, Monza, Torino, Padova, Siena, Catania, Florence

2023-12-11

Active, closed

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma

DrugBel-sar

Aura Biosciences

Phase 3

108

Florence, Milan, Roma

2023-12-06

Active, closed

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

NCT05993234HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma

DrugTrastuzumab deruxtecan

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Observational

257

Castellana Grotte, Catania, Florence, Genova, Milan, Modena, Naples, Pisa

2023-12-05

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Florence, Milan, Padova, Pisa, Rozzano, Tricase, Lecce

2023-12-04

Active, closed

A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

NCT06514807Essential Thrombocythaemia

DrugBesremi

AOP Orphan Pharmaceuticals AG

Phase 3

117

Bologna, Florence, Rome, Turin

2023-12-04

Recruiting

A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment

NCT06192563Atopic Dermatitis

DrugDupilumab

Sanofi

Observational

230

Bologna, Brescia, Florence, Milan, Naples, Roma, Verona

2023-11-30

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Florence, Gussago, Messina, Novara, Orbassano, Palermo, Pavia, Pisa

2023-11-29

Recruiting

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

NCT05935358Severe Hemophilia A

DrugNuwiq

Octapharma

Phase 4

Catanzaro, Florence, Milan

2023-11-28

Recruiting

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

NCT05694312Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Monoclonal B-Cell Lymphocytosis CLL-Type

DrugIbrutinib

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

Florence, Novara, Torino

2023-11-24

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsSotorasib·Pembrolizumab

Amgen

Phase 3

750

Bari, Brescia, Candiolo, Catania, Florence, Meldola (FC), Milan, Monza (MB)

2023-11-16

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Rozzano, Bari, Bologna, Florence, Genova, Milan, Naples, Novara

2023-11-14

Recruiting

Sensory and Cognitive Outcomes of Robotic Exercises in Stroke (SCORES)

NCT06109324Stroke

Fondazione Don Carlo Gnocchi ETS

Not applicable

126

Florence, Messina, Roma

2023-11-13

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

L’Aquila, Florence, Milan, Roma, Rome, Cagliari

2023-11-08

Active, closed

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907Ulcerative Colitis

DrugUpadacitinib

AbbVie

Phase 3

122

Florence, Rome, Bologna

2023-11-06

Active, closed

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

NCT06054555Melanoma

DrugsOpdivo·Nivolumab

Amgen

Phase 3

633

Crema, Meldola, Taormina, Rozzano, Alessandria, Bari, Bergamo, Florence

2023-11-02

Recruiting

Psychosomatic Intervention in Fibromyalgia.

NCT06135753Fibromyalgia

University of Florence

Not applicable

100

Florence

2023-11-01

Recruiting

Predictive Variables of Outcome in Subjects With Chronic Rachialgia Referred to Different Pathways of Physiotherapy.

NCT06915896Chronic Non-Specific Low Back Pain, Chronic Non-specific Neck Pain

Fondazione Don Carlo Gnocchi ETS

Observational

200

Florence

2023-10-30

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Ancona, Modena, Florence, Milan, Pisa, Roma, Trieste, Bergamo

2023-10-25

Active, closed

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT05949684Myelodysplastic Syndromes

DrugsEpoetin Alfa·Reblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

402

Rome, Milan, Rozzano, Turin, Florence, Bologna, Reggio Calabria, Roma

2023-10-24

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Florence, L’Aquila, Rozzano, Naples, Rome, Bologna, Brescia, Catania

2023-10-11

Recruiting

European Newborn Study: Early Markers for a Better LifE

NCT07189494Cerebral Palsy

dr. M.J.N.L. Benders

Observational

1,000

Florence, Genova, Milan, Pisa

2023-10-06

Active, closed

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

106

Reggio Calabria, Naples, Rome, Pavia, Rozzano (MI), Novara, Turin, Florence

2023-10-05

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Bergamo, Bologna, Florence, Genoa, Meldola, Milan, Misterbianco, Monza

2023-10-05

By invitation

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 3

306

Florence, Milan

2023-10-03

Recruiting

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

NCT05609630Juvenile Idiopathic Arthritis

DrugsUpadacitinib·Tocilizumab

AbbVie

Phase 3

Florence, Genoa

2023-10-02

Recruiting

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

NCT05957367GIST

DrugRipretinib

Deciphera Pharmaceuticals, LLC

Phase 1/2

Florence, Genova, Milan

2023-09-28

Active, closed

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT05936359Myeloproliferative Neoplasms

DrugsINCA033989·Ruxolitinib

Incyte Corporation

Phase 1

160

Bologna, Florence, Milan

2023-09-25

Active, closed

MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect

NCT05816122Multiple Sclerosis

Ad scientiam

Not applicable

336

Florence, Foggia, Milan

2023-09-22

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671Locally Advanced Cervical Cancer

DrugVolrustomig

AstraZeneca

Phase 3

800

Bari, Bologna, Catania, Florence, Lecco, Milan, Monza, Naples

2023-09-22

Active, closed

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT05822752Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Sorafenib·Lenvatinib

AbbVie

Phase 2

130

Florence, Milan, Naples, Bologna, Palermo, Roma

2023-09-21

Recruiting

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

NCT05816850Follicular Lymphoma

Fondazione Italiana Linfomi - ETS

Observational

654

Alessandria, Biella, Brescia, Catania, Cuneo, Florence, Genova, Meldola

2023-09-19

Recruiting

Robotic Rehabilitation Vs Occupational Therapy Chronic Stroke Upper Limb Rehabilitation

NCT06884553Chronic Stroke

University of Florence

Not applicable

Florence

2023-09-19

Active, closed

First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

NCT06121401Carcinoma, Ovarian Epithelial

DrugsOlaparib·Bevacizumab

Mario Negri Institute for Pharmacological Research

Phase 4

190

San Fermo della Battaglia, Brescia, Florence, Lecco, Lucca, Milan, Padova, Parma

2023-09-15

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Bologna, Modena, Florence, Milan, Pisa, Roma, Ancona, Bergamo

2023-09-14

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic

DrugBelimumab

GlaxoSmithKline

Phase 2/3

300

Roma, Ancona, Bari, Cagliari, Catania, Ferrara, Florence, Milan

2023-09-13

Active, closed

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

NCT05846230Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 2

268

Florence, Palermo, Pavia, Rozzano (MI), Verona

2023-09-08

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

NCT06047171Glomerulonephritis Rapidly Progressive

DrugsCyclophosphamid·Rituximab

Alentis Therapeutics AG

Phase 2

Bergamo, Florence, Milan, Rome, Trento

2023-09-07

Recruiting

The ReTAVI Prospective Observational Registry

NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction

Institut für Pharmakologie und Präventive Medizin

Observational

250

Ancona, Bologna, Brescia, Florence, Milan, Padua, Pisa, Roma

2023-09-05

Recruiting

A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

NCT06092034Danon Disease

Rocket Pharmaceuticals Inc.

Phase 2

Florence

2023-09-05

Active, closed

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 3

500

San Donato Milanese, Brescia, Florence, Foggia, Milan, Naples, Pisa, Roma

2023-08-31

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

DrugZipalertinib

Taiho Oncology, Inc.

Phase 2

220

Florence, Meldola, Cremona, Milan, Parma, Ravenna

2023-07-31

Active, closed

Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL

NCT05478512High Risk CLL, Chronic Lymphocytic Leukemia

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

Florence, Meldola, Perugia, Ravenna, Rimini, Roma, Siena

2023-07-21

Recruiting

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1,000

Salerno, Rome, Brescia, Milan, Baggiovara, Ponderano (Biella), Florence, Monza

2023-07-11

Active, closed

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

100

Florence, Pavia, Siena

2023-07-11

Recruiting

Validation, Implementation, and Cost-analysis of a Strategy for Personalized Diagnosis of Rare Kidney Diseases

NCT06324136Chronic Kidney Diseases

Meyer Children's Hospital IRCCS

Not applicable

300

Florence, Naples, Palermo

2023-07-06

Recruiting

Molecular Characterizazion and Biological Samples Centralisation of Patients Affected by Oncoematolofic Pathology

NCT06304194Oncologic Disease, Hematologic Diseases

Meyer Children's Hospital IRCCS

Not applicable

340

Florence, Pisa, Siena

2023-07-05

Recruiting

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

NCT05592938Breast Cancer, Breast Cancer Recurrent

University Health Network, Toronto

Not applicable

171

Florence

2023-06-27

Recruiting

Use of Shockwave M5+/L6 IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access

NCT05880641Aortic Diseases, Aorto-Iliac Atherosclerosis, Peripheral Arterial Disease

EndoCore Lab s.r.l.

Observational

Ancona, Bologna, Rome, Florence, Perugia, Padova

2023-06-26

Active, closed

A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT05776472Paroxysmal Nocturnal Hemoglobinuria

DrugPegcetacoplan

Swedish Orphan Biovitrum

Observational

165

Bari, Bassano del Grappa, Bologna, Cagliari, Florence, Milan, Novara, Reggio Calabria

2023-06-26

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Catania, Florence, Genova, Milan, Pisa, Roma, Torino, Naples

2023-06-22

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

Cona, Florence, L’Aquila, Rome, Brescia, Milan, Modena, Pisa

2023-06-21

Recruiting

A Retrospective Study to Characterize Participants With Propionic Acidemia

NCT05769621Propionic Acidemia

ModernaTX, Inc.

Observational

Naples, Monza, Florence

2023-06-16

Recruiting

Gepant treAtments: EffectIveNess and tolERability (GAINER)

NCT05903027Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine

University of Florence

Observational

100

Florence, Pavia

2023-06-15

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

NCT05841537Crohn's Disease

AbbVie

Observational

1,019

Florence, Rozzano, Milan, Rome, Bari, Bologna, Messina

2023-06-09

Active, closed

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

Alexion Pharmaceuticals, Inc.

Phase 3

165

Bologna, Florence, Milan, Pisa, Roma

2023-06-07

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction

DrugVericiguat

Merck Sharp & Dohme LLC

Phase 2/3

342

Genoa, Milan, Turin, Rome, Florence, Padova

2023-05-31

Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT05442567Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

240

Naples, Bologna, Rome, Monza, Florence, Padova

2023-05-16

Recruiting

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

NCT05562466Asthma

DrugBudesonide

Novartis Pharmaceuticals

Phase 3

200

Brescia, Catania, Florence, Pavia, Roma, Naples

2023-05-11

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

Bologna, Florence, Milan, Naples, Reggio Emilia, Roma, Rozzano, San Giovanni Rotondo

2023-05-03

Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

NCT06805812Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma

DrugsAbemaciclib·Ribociclib·Palbociclib

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Observational

3,500

Aviano, Brescia, Catania, Como, Cremona, Florence, Genova, Meldola

2023-05-01

Active, closed

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer

DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine

AstraZeneca

Phase 2

294

Florence, Milan, Naples, Rozzano

2023-04-24

Recruiting

Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

NCT05817903Metastatic Renal Cell Carcinoma

DrugsAxitinib·Nivolumab

Consorzio Oncotech

Phase 2

118

Brescia, Candiolo, Catania, Cremona, Florence, Genova, Milan, Modena

2023-04-18

Recruiting

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

Weill Medical College of Cornell University

Not applicable

2,300

Bari, Bergamo, Brescia, Cotignola, Florence, Roma, Torino

2023-04-17

Recruiting

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

NCT05555589Neurotrophic Keratopathy

ReGenTree, LLC

Phase 3

Brescia, Florence

2023-04-11

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

Bari, Catania, Catanzaro, Florence, Genova, Grosseto, Milan, Modena

2023-03-31

Recruiting

The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases

NCT06325059Nephropathy

Meyer Children's Hospital IRCCS

Not applicable

200

Florence

2023-03-22

Recruiting

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

NCT05259605Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Observational

1,650

Bologna, Florence, Milan, Padova, Roma, Torino

2023-03-21

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

Florence, Meldola, Genoa, Rozzano, Milan, Naples, Rome, Mirano

2023-03-15

Recruiting

BPH Global Registry

NCT05543200Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms

Société Internationale d'Urologie

Observational

7,500

Florence, Rome

2023-03-13

Active, closed

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

14,012

Ancona, Brescia, Caserta, Chieti, Catanzaro, Florence, Chiavari, Genova

2023-03-09

Recruiting

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

NCT05744921Paroxysmal Nocturnal Hemoglobinuria

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

202

Florence, Torino

2023-03-07

Active, closed

Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

NCT05818943GRIN-related Disorders

DrugRadiprodil

GRIN Therapeutics, Inc.

Phase 1

Rome, Florence

2023-03-07

Active, closed

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

NCT05548062Polycythemia Vera

Novartis Pharmaceuticals

Observational

242

Alessandria, Ancona, Bari, Bologna, Como, Cosenza, Catania, Florence

2023-03-02

Recruiting

An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

NCT06720870Castleman Disease

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

Bologna, Caserta, Bari, Ferrara, Florence, Milan, Novara, Padova

2023-03-01

Active, closed

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

DrugsSpartalizumab·Decitabine·Azacitidine·Venetoclax

Novartis Pharmaceuticals

Phase 2

Brescia, Florence, Genova, Milan, Roma

2023-02-28

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Milan, Roma, Torino, Bari, Florence, Genova, Naples, Padova

2023-02-27

Active, closed

VIATORR Device Registry

NCT05661331Chronic Liver Disease

W.L.Gore & Associates

Observational

196

Florence, Modena

2023-02-21

Active, closed

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

NCT05685238Haemophilia A, Haemophilia A With Inhibitors

Novo Nordisk A/S

Phase 3

451

Rome, Florence, Milan, Naples, Roma, Torino

2023-02-13

Recruiting

Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation

NCT06813443Cardiomyopathies, Amyloidosis Cardiac, Fabry Disease, Arrhythmogenic Cardiomyopathy

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

700

Bologna, Roma, Florence

2023-02-13

Recruiting

Pulmonary Rehabilitation in the Chronically Critically Ill Patient

NCT06453421Rehabilitation, Chronic Critical Illness

Fondazione Don Carlo Gnocchi ETS

Observational

220

Florence

2023-02-10

Active, closed

Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

NCT04882475Mantle Cell Lymphoma

Fondazione Italiana Linfomi - ETS

Observational

160

Milan, Siena, Aviano, Brescia, Cuneo, Florence, Novara, Padova

2023-02-08

Active, closed

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

NCT05609968Carcinoma, Non-Small-Cell Lung

DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Rome, Bergamo, Milan, Naples, Florence, Peschiera del Garda, Parma

2023-02-06

Active, closed

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

NCT05653349Primary Immune Thrombocytopenia (ITP)

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

226

Bologna, Florence, Roma, Trieste, Vicenza

2023-02-03

Recruiting

Preoperative vs Postoperative Hypofractionated Radiosurgery for Patients With Large Brain Metastases

NCT05545007Brain Metastases, Adult

Istituto Clinico Humanitas

Not applicable

146

Brescia, Florence, Rozzano, Milan, Naples, Rome, Terni

2023-01-31

Active, closed

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

NCT05662241IgG4 Related Disease

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 3

194

Turin, Brescia, Florence, Milan, Verona

2023-01-09

Active, closed

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease

DrugGSK4532990

GlaxoSmithKline

Phase 2

284

Florence, Milan, Modena, Padova, Palermo, Roma, Rozzano MI, San Giovanni Rotondo FG

2023-01-02

Active, closed

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

NCT05024773Bladder Carcinoma in Situ (CIS)

Fidia Farmaceutici s.p.a.

Phase 3

130

Bergamo, Bologna, Castelfranco Veneto, Florence, Lecce, Milan, Naples, Roma

2022-12-29

Active, closed

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NCT05687266NSCLC

DrugsDato-DXd·Durvalumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 3

1,350

Florence, Lecco, Messina, Naples, Orbassano, Padova, Parma, Peschiera del Garda

2022-12-29

Active, closed

Pectus Excavatum Camouflage (IT)

NCT05634070Pectus Excavatum

BellaSeno GmbH

Not applicable

Florence

2022-12-28

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

Ancona, Bologna, Brescia, Cagliari, Caserta, Catanzaro, Cinisello Balsamo, Florence

2022-12-27

Recruiting

Multicenter Italian Cohort Study on Tuberculosis in Pediatric Age

NCT06289660Tuberculosis Infection

Meyer Children's Hospital IRCCS

Observational

1,000

Florence, Bari, Belluno, Bologna, Genova, Milan, Modena, Naples

2022-12-22

Recruiting

Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastrectomies for Gastric Cancer (PhotoNodes)

NCT06466902Gastric Cancer, Gastric Adenocarcinoma, Lymphadenectomy, Minimally Invasive Surgery

Azienda Ospedaliero-Universitaria di Parma

Observational

326

Cremona, Florence, Milan, Abano Terme, Verona, Parma

2022-12-22

Recruiting

European Myeloma Network (EMN) Sample Project

NCT06237803Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma

European Myeloma Network B.V.

Observational

6,000

Alessandria, Ancona, Bari, Bologna, Brescia, Civitanova Marche, Florence, Genova

2022-12-21

Recruiting

COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

NCT05633810Diabete Type 2, Cardiovascular Diseases

DrugsColchicine·Aspirin

Montreal Heart Institute

Phase 3

10,000

Foggia, Acquaviva delle Fonti, Ferrara, Ravenna, Milan, Turin, Ancona, Florence

2022-12-21

Recruiting

Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma

NCT06806579Hepatocellular Carcinoma (HCC)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

1,000

Torrette, Castellana Grotte, Bologna, Catania, Foggia, Florence, Modena, Milan

2022-12-21

Recruiting

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

NCT05640999Endometrial Cancer

Canadian Cancer Trials Group

Phase 2

393

Florence, Brescia, Lecco, Milan, Rome

2022-12-19

Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-italy/city/florence

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 787 of those studies with a site in Florence.

How many clinical trials are recruiting in Florence?

435 of the 787 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 30 have not yet opened recruitment, 305 are active but closed to new participants, and 17 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Florence), 787 studies
Phase	Studies	Recruiting	Share
Phase 3	335	152	42.6%
Observational	184	136	23.4%
Phase 2	110	52	14%
Not applicable	86	55	10.9%
Phase 2/3	30	18	3.8%
Phase 1/2	19	11	2.4%
Phase 4	14	7	1.8%
Phase 1	9	4	1.1%

Most active sponsors

Lead sponsors with the most studies (Florence)
Lead sponsor	Studies	Recruiting
AstraZeneca	57	27
Meyer Children's Hospital IRCCS	41	37
Eli Lilly and Company	25	14
Merck Sharp & Dohme LLC	25	12
Novartis Pharmaceuticals	24	10
Fondazione Don Carlo Gnocchi ETS	21	13
Bristol-Myers Squibb	17	2
Azienda Ospedaliero-Universitaria Careggi	16	10
Janssen Research & Development, LLC	16	6
AbbVie	15	5

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.